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ABSTRACT
THE IMPACT OF PTSD AND HISTORY OF INVOLVEMENT IN THE
CRIMINAL JUSTICE SYSTEM ON MEDICATION TREATMENT SUCCESS IN
OPIOID USE DISORDER
FEBRUARY 2019
KIRK SANGER, B.A., KEENE STATE COLLEGE
B.S., UNIVERSITY OF MASSACHUSETTS AMHERST
M.M., LONGY SCHOOL OF MUSIC AT BARD COLLEGE
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Lisa Chiodo, Ph.D.
This analysis examined the impact of post-traumatic stress disorder (PTSD),
history of trauma, and a history of involvement in the criminal justice system (CJS) on
treatment outcomes related to medication treatment for opioid use disorder. This study
employed a secondary analysis of data derived from a multi-state, multi-site treatment
center focused on substance abuse and more specifically opioid use disorder treatment.
The total sample size was 19,970 patients. The majority of the sample received treatment
in Massachusetts, was white, and non-Hispanic. Those with PTSD accounted for 9.5% of
the sample, while 12% had a history of trauma. Just under 1/4th of the sample had a
history of involvement in the criminal justice system. All individuals in the sample were
treated with buprenorphine and were expected to participate in both individual and group
meetings related to their treatment.
Patients with a history of PTSD and trauma were more adherent with
buprenorphine, but also more likely to use opioids than those without PTSD or trauma.
Those with CJS involvement were more medication adherent and less likely to use
opioids than those without a CJS involvement. All three risk groups were found to have
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significant difficulty meeting other treatment visit compliance measures such as
attendance to individual and group visits, had overall higher rates of total number of
encounters, and were more likely to cancel their visits. PTSD and trauma moderated the
relationship between CJS history and medication adherence and CJS history and opioid
use. PTSD and trauma moderated the relationship between CJS history and other
compliance indicators (e.g., number of initial visits and number of induction visits).
Gender also moderated some of the relationships examined with women having more noshow visits, rescheduled visits more often and had higher rates of overall number of
encounters. Women in particular failed to attended scheduled individual and group
treatment sessions and spent more time in care. Women also had higher rates of PTSD
and trauma.
The results have implications for clinicians caring for patients with OUD and
patients with a history of incarceration. Assessing for and acknowledging trauma will
allow those clinicians to implement patient-centered, trauma informed treatment models
to deliver focused care to these specific populations that are struggling to meet treatment
compliance measures.
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CHAPTER 1
OPIOID USE DISORDER, POST-TRAUMATIC STRESS,
AND INVOLVEMENT IN THE CRIMINAL JUSTICE SYSTEM
Introduction
In America, 20.5 million people over the age of 12 have a Substance Use Disorder
(SUD) (Center for Behavioral Health Statistics and Quality, 2016). Of those, over 2.1
million people have an opioid use disorder (OUD), while over 545,000 people have a
dependency to heroin in the U.S. (NIDA, 2015). In 2016, approximately 948,000 people
had at a minimum tried heroin, while it was estimated that 11.8 million people had
misused a pain reliever, most of which were opioid based (Substance Abuse and Mental
Health Services Administration, 2017).
Opioid addiction can lead to death, criminality, numerous co-morbidities, reincarceration for previously incarcerated individuals, increased exposure to HIV and
hepatitis C, and neonatal abstinence syndrome for newborns (NIDA, 2015).
Post-Traumatic Stress (PTS) and addiction typically co-occur (Danovitch, 2016;
Hildebrand, Behrendt, & Hoyer, 2015). Co-occurring PTS further exacerbates an existing
problem for those with and OUD and leads to reduced treatment outcomes (Meier et al.,
2014). Of those 20.5 million with an SUD, approximately 1.4 million are currently
incarcerated individuals (Fox, 2015). Of those prisoners, approximately 40% report
having Post-Traumatic Stress (Flatt, Williams, Barnes, Goldenson, & Ahalt, 2016).
Those who were already exposed to trauma before incarceration also show increase of
trauma symptoms while incarcerated (Schappell, Docherty, & Boxer, 2016). PTS itself if
is a risk factor for increased incarceration. Having PTS increases the odds of being
arrested, jailed, imprisoned, and having experienced at least four or more incidents of
trauma (Jäggi, Mezuk, Watkins, & Jackson, 2016).
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Understanding the relationships between opioid addiction, post-traumatic stress,
and having a history of incarceration is imperative to successfully treating individuals
that are struggling with addiction and are participating in medication treatment (MT).
Background of the Problem
Opioid Use Disorder
In the years from 1999-2015, the United States witnessed a four-fold increase in
both the overdose deaths from opioids and heroin with a total of 33,091 deaths
(O’Donnell, Gladden, & Seth, 2017). Opioid related deaths now account for the largest
number of accidental deaths in the United States. While methadone related deaths since
2008 have decreased, there has been an increase in deaths related to heroin, illicitly
manufactured Fentanyl, and abuse of other synthetic opioids (Rudd, Seth, David, &
Scholl, 2016). An increase in the prescribing of opioids over the past 15-20 years has
contributed to increasing rates of addiction and mortality due to nonmedical use of
prescription opioids. There is also strong evidence that the nonmedical use of
prescription opioids is often followed by the use of heroin (Compton, Jones, & Baldwin,
2016).
As of 2013, taking into account health insurance costs, loss of life and thus
productivity, substance abuse treatment, and criminal justice costs, researchers at the
Centers for Disease Control (CDC) estimate the U.S. economic burden to be
approximately $78.5 billion (Florence, Zhou, Luo, & Xu, 2016). We can only assume
that as the opioid mortality rate continues to increase, so will this estimate.
OUD and Post-Traumatic Stress
Trauma is more often an antecedent to the use of opioids (Hassan, Foll, Imtiaz, &
Rehm, 2017). Survivors of trauma, looking for a way to cope, use opioids or other drugs
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and alcohol to self-medicate (Henwood & Padgett, 2007). Co-occurring Post-Traumatic
Stress Disorder (PTSD) results in poorer treatment outcomes than for patients without
symptoms of PTSD (Meier et al., 2014). More problematic is the reciprocal relationship
between withdrawing from opioids and an increased stress response. Those with an
OUD, often use opioids in response to increased stress. While those withdrawing from
opioids can experience large amounts of stress. Therefore, refraining from opioid use
while withdrawing can be extremely challenging and stressful. This can often lead to
increased use (Danovitch, 2016; Hassan et al., 2017).
Gender Differences in OUD and PTS
Women are at a greater risk of experiencing trauma through sexual violence,
emotional and physical abuse, and experiencing trauma at younger age. There are
marked gender differences within OUD both for patients with and without PTS. PTS also
has a role in partially mediating the relationship of women’s substance use with violent
offending (Howard, Karatzias, Power, & Mahoney, 2017). As women with PTS continue
to use substances and commit violence, they are as a consequence, more likely to have a
history of incarceration (Komarovskaya, Booker Loper, Warren, & Jackson, 2011).
Women are more likely to be diagnosed with post-traumatic stress, substance abuse, and
depression (Al-Rousan, Rubenstein, Sieleni, Deol, & Wallace, 2017).
While there has been variation in outcomes for those in concurrent treatment for
SUD and PTS, there have been significant improvements for those receiving trauma
focused dual treatment with attrition rates being the same across all groups (Killeen,
Back, & Brady, 2015). Clinicians agree that there is a need for concurrent treatment,
however are not in agreement as to how treatment should progress, especially in cases of
severe trauma. The concern is notably whether or not the person re-experiences trauma
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during therapy and thus desires to re-abuse substances to relieve said trauma (L. M.
Najavits, Kivlahan, & Kosten, 2011).
Persons with Involvement in the Criminal Justice System and PTSD
While 18% of the overall incarcerated population will present with some mental
health diagnosis (Al-Rousan et al., 2017), incarceration itself has implications to expose
inmates to trauma while incarcerated (Beck, Berzofsky, Caspar, & Krebs, 2013). People
who have been incarcerated or are presently incarcerated often feel unsafe, exhibit
increased anti-social behavior, and symptoms of trauma due to circumstances related to
but not limited to childhood trauma, domestic violence, and military violence preincarceration (Schappell et al., 2016).
OUD and Involvement in the Criminal Justice System
Entering the penal system in the United States while suffering with an OUD
presents one of several situations and depends whether that person is incarcerated in a
federal prison or a state run correctional facility. Not providing an MT at the beginning
of incarceration has long-term implications for increased mortality and suicidality in the
first few weeks of the incarceration experience (Larney et al., 2014; Rivlin, Ferris,
Marzano, Fazel, & Hawton, 2013).
Federal Prison
Following a framework of abstinence from opioids, the United States Bureau of
Prisons (BOP) directs clinicians within the federal prison system on a prescribed method
for detoxification of inmates who present with a current SUD (Federal Bureau of Prisons,
2014).
Methadone is the recommended course of treatment until the cessation of
withdrawal symptoms, followed by a 10% taper daily until the Methadone is
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discontinued. Typically, adjunct treatment is included only for withdrawal symptoms in
the form of Clonidine, as well as anti-inflammatories, antipyretics, anti-emetics, and antianxiety medication, but not a long-term opioid medical maintenance treatment. This will
at times allow for a controlled withdrawal and symptom management, however does not
assist long-term recovery during their incarceration or after re-entry.
State Correctional Facilities
Each state has their own policy regarding the use of MT within the correctional
system. Depending on the particular state, some correctional facilities provide MT, while
others do not (Aronowitz & Laurent, 2016). Treatment with continued opioid
maintenance agonists such as methadone, or antagonists such naltrexone or a mix of the
two, buprenorphine, is still not prevalent within the U.S. correctional system even though
these methods are effective evidence-based medical practices. There are few instances
where jails or prisons are providing viable treatments for incarcerated populations with an
OUD. Treating inmates during their incarceration has lasting effects during the
incarceration experience as well as post-release (Rich et al. 2015).
Persons with Involvement in the CJS and Medication Treatment
Exiting the correctional system with an OUD significantly puts individuals at
higher risk for increased medical issues and re-incarceration, but also death (Binswanger
et al., 2016; Marsden et al., 2017; Merrall et al., 2010). The risk appears to be heightened
for younger people, women more specifically. In a study of 42,015 recently released
individuals, 14,920 of which were young prisoners (<25yr), Van Dooren, Kinner, &
Forsyth (2013) determined that the younger group was less at risk for mortality than
older, previously incarcerated individuals. However, poisoning by drugs was the leading
cause of death for the younger group with men at 43% and women 50%. More
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specifically, the younger group, when compared to peers in their community at similar
ages, were six times as likely to die. The women in the younger group were 20 times as
likely to die then their community peers.
Studies are limited examining the outcomes of MT among incarcerated
individuals. There are some however that demonstrate the effectiveness of MT both in the
correctional setting and upon re-entering the community. These studies have
demonstrated positive results in terms of overall health, reduction in mortality, and
reduction in re-offending post-release (Degenhardt et al., 2014; Gisev et al., 2015;
Larney, Toson, Burns, & Dolan, 2012; Marsden et al., 2017). While MT has been shown
to be successful as a treatment modality for incarcerated prisoners evidenced by a lower
recidivism rate, a decrease in cravings for opioids, and lower rates of sexually transmitted
infections (Aronowitz & Laurent, 2016).
It is clear from previous research that MT is successful for some groups.
However, when considering the effects of PTSD, trauma, and an involvement in the
criminal justice system, it becomes clear that there is not a complete understanding of
what those effects mean for those that have an OUD while also living with PTSD, a
history of trauma, or a past involvement in the criminal justice system. Understanding
these relationships may allow practitioners that ability to deliver more applicable
treatment to these groups.
Significance of the Study
Opioid addiction can lead to death, criminality, numerous co-morbidities, reincarceration for previously incarcerated individuals, increased exposure to HIV and
hepatitis C, and neonatal abstinence syndrome for newborns (NIDA, 2015).
Approximately 30% of the people in seeking treatment for their opioid addiction have a
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diagnosis of PTSD (Ecker, Hundt, Ecker, & Hundt, 2017). Additionally, 50% of those
people seeking treatment for OUD have an involvement in the criminal justice system
(Winkelman et al., 2016) and 80% have a diagnosis related to an anxiety disorder (Brady,
Haynes, & Killeen, 2013).
MT has demonstrated success among those in treatment in the form of agonist and
antagonist therapy for long-term recovery (Hser, Evans, Grella, Ling, & Anglin, 2015b).
This approach to MT is often combined with individual or group counseling techniques
aimed at allowing the patient to change their neurobiology as well as their cognitive
relationship to opiates. At times this has increased retention within combined treatment
programs (Timko, Schultz, Cucciare, Vittorio, & Garrison-Diehn, 2016). However, this
may actually inhibit successful treatment of PTSD as this may interrupt the development
of coping skills (Danovitch, 2016; Saunders et al., 2015a). Understanding these
relationships more clearly will enable clinicians to intervene more appropriately when
presented with someone with co-occurring PTSD and participating in MT.
Understanding how these interactions affect those with involvement in the criminal
justice system who are in the process of recovery will aid in long term success.
Developing a clearer understanding and framework for treatment within this
smaller subset of the population may allow clinicians to treat other groups of individuals
suffering from the combination of PTSD and OUD. Veterans, sexual abuse survivors,
refugees, or other individuals living with PTSD and OUD will benefit from the
approaches and practices that can instituted with the knowledge from this proposed study.
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Purpose
The purpose of this study is to explore the relationships between Opioid Use
Disorder, Post-Traumatic Stress, involvement in the criminal justice system, and MT
treatment success.
Study Aims and Hypotheses
To achieve the study goal, this proposal will examine the following aims and
hypotheses in a sample of Opioid Use Disorder patients receiving MT. For all aims, the
following outcome variables will be examined: treatment compliance (the number no
show visits, number maintenance visits, number of initial visits, number of rejoin visits,
number of induction visits, number of group visits, number of no show group visits,
number of group cancellations, number of rescheduled visits, number of interruptions,
number of other encounters, total time in care, and the time since the last visit),
medication adherence, and drug use (opioids, cocaine, THC, methadone,
benzodiazepines, alcohol, amphetamines, cocaine, other drugs. Other drugs included
PCP, barbiturates, methamphetamines, and ecstasy.
Aim 1: To compare outcomes of Medication treatment (MT) success in patients with
elevated post-traumatic stress (PTS) and patients without PTS.
H1a-m. Patients with evidence of PTS will have lower rates of treatment compliance
than patients without evidence of PTS.
PTS+

¯ Treatment Compliance

H1n. Patients with evidence of PTS will have a lower rates of medication adherence
compared to patients without evidence of PTS.
PTS+

¯ Medication Adherence
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H1o. Patients with evidence of PTS will have an increase in drug use than patients
without evidence of PTS.
 Drug Use

PTS+

Aim 2: To compare outcomes of Medication treatment (MT) success in patients with
a history of trauma (Trauma+) and patients without a history of trauma.
H2a-m. Patients with evidence of Trauma will have lower rates of treatment
compliance than patients without evidence of Trauma.
Trauma+

¯ Treatment Compliance

H2n. Patients with evidence of Trauma will have a lower rates of medication
adherence compared to patients without evidence of Trauma.
Trauma+

¯ Medication Adherence
H2o. Patients

with evidence of Trauma will have an increase in drug use than patients without
evidence of Trauma.
 Drug Use

Trauma+

Aim 3: To compare outcomes of Medication treatment (MT) success in patients
with a history of involvement with the criminal justice system (CJS) and patients
without a history of involvement in CJS.
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H3a-m. Patients with involvement in the criminal justice system will have lower rates
of treatment compliance than patients without involvement in the criminal justice
system.
Treatment Compliance

Involvement in CJS+

H3n. Patients with involvement in the criminal justice system will have lower rates of
medication adherence compared to patients without involvement in the criminal
justice system.
¯ Medication Adherence

Involvement in CJS+

H3o. Patients with an involvement in CJS will have an increase in drug use than patients
without involvement in the criminal justice system.
Involvement in CJS+

 Drug Use

Aim 4. To examine if PTS status moderates the relationship between involvement in
the criminal justice system and Medication Treatment success.
H5a-m. The relationship between involvement in the criminal justice system and
provider visit compliance will be moderated by PTS status.
Involvement in CJS+

¯ Treatment Compliance

PTS+
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H5n. The relationship between involvement in the criminal justice system and
medication adherence will be moderated by PTS status.
¯ Medication Adherence

Involvement in CJS+

PTS+

H5o. The relationship between involvement in the criminal justice system and drug
use will not be moderated by PTS status.
↑ Drug Use

Involvement in CJS+

PTS+

Aim 5. To examine if trauma status moderates the relationship between involvement
in the criminal justice system and Medication Treatment success.
H6a-m. The relationship between involvement in the criminal justice system and
treatment compliance will be moderated by trauma status.
Involvement in CJS+

¯ Treatment Compliance

Trauma+
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H6n. The relationship between involvement in the criminal justice system and
medication adherence will be moderated by trauma status.
¯ Medication Adherence

Involvement in CJS+

Trauma+

H6o. The relationship between involvement in the criminal justice system and drug
use will not be moderated by trauma status.
↑ Drug Use

Involvement in CJS+

Trauma+

In addition to the above aim, the influence of gender on the impact of PTS+ or trauma on
the relationship between buprenorphine and treatment success was examined.
Summary
Given the substantial personal and societal impact of opioid use, understanding
factors that might impact MT treatment is critical. Understanding if factors such as PTS
and CJS status will lead to poorer OUD treatment success provides an opportunity for the
development of interventions to increase treatment retention and success for all
individuals with OUD. In addition, understanding the relationship of PTS, CJS and MT
treatment will allow clinicians the opportunity to provide evidence-based treatment to a
very deserving population.
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CHAPTER 2
REVIEW OF LITERATURE AND THEORETICAL FRAMEWORK
This chapter provides on overview of the complexities of opioid use disorder
(OUD), co-occurring post-traumatic stress (PTS), and having a history of incarceration.
This is a review of the literature as it pertains to the relationships of OUD, post-traumatic
stress, incarceration, and medical management of OUD. I utilize a theoretical framework
developed by Lazarus and Folkman – the Transactional Stress theory as it relates to
treatment of opioid use disorder will having co-occurring post-traumatic stress, trauma,
and an involvement in the criminal justice system.
Introduction
In America, 20.5 million people over the age of 12 have a Substance Use Disorder
(SUD) (Center for Behavioral Health Statistics and Quality, 2016). Of those, over 2.1
million people had an opioid use disorder (OUD), while over 545,000 people are
dependent on heroin in the U.S. (NIDA, 2015). Opioid addiction can lead to death,
criminality, numerous co-morbidities, re-incarceration for previously incarcerated
individuals, increased exposure to HIV and hepatitis C, and neonatal abstinence
syndrome for newborns (NIDA, 2015). In 2016, approximately 948,000 people had at a
minimum tried heroin, while it was estimated that 11.8 million people had misused a pain
reliever, most of which were opioid based (Substance Abuse and Mental Health Services
Administration, 2017).
Post-Traumatic Stress (PTS) and addiction typically co-occur (Danovitch, 2016;
Hildebrand et al., 2015). Co-occurring PTS further exacerbates an existing problem for
those with and OUD and leads to reduced treatment outcomes (Meier et al., 2014). Of
those 20.5 million with a SUD, approximately 1.4 million are currently incarcerated
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individuals (Fox, 2015). Of those prisoners, approximately 40% report having PostTraumatic Stress (Flatt et al., 2016). Those who were already exposed to trauma before
incarceration also show an increase of trauma symptoms while incarcerated (Schappell et
al., 2016). PTS itself is a risk factor for increased incarceration. This is especially
evident for black men. Having PTS increases the odds of being arrested, jailed,
imprisoned, and having experienced at least four or more incidents of trauma (Jäggi et al.,
2016).
Understanding the relationships between opioid addiction, post-traumatic stress,
and having a history of incarceration is imperative to successfully treating individuals
that are struggling with PTS, addiction and are receiving medication treatment (MT).
Background of the Problem – Opioid Use
Opioid use in not a new phenomenon. The medicinal origins of opioid use can be
traced back as early as 1,500 B.C. (Brownstein, 1993). During antiquity, opium poppies
used on statues and in paintings, represented sleep and death (Tekiner & Kosar, 2016).
More formalized in the sixteenth-century, the social use of ‘laudanum’, a potent mix of
opium (later replaced by morphine) and alcohol, was reserved for the social elite
(Heyman, 2009). Physicians, as they do today, played a role in perpetuating the uses and
efficacy of opiates for numerous ailments (Kulich & Loeser, 2011). These were at times
reasonable and at other times bordered on the farfetched. These ailments included: pain,
sleep, headaches, menstrual cramping, diarrhea, insanity, and even used to treat
tuberculosis among other infective diseases (Postler & Waisel, 1997).
While opium was already widely used, it gained recognition as an addictive
substance in the late eighteenth-century and was responsible for creating a schism in the
trade economy between Britain and China. As Britain pushed more opium into China in
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exchange for silver, more of the Chinese population became dependent on the substance.
China became well aware of the physical and mental distress enacted on their citizens
who had become overwhelmed by the substance causing conflict in what would go on to
be known as the Opium Wars (Caquet, 2015).
This has continued to present day where the reasons people use and abuse opioids,
be it prescription or illegal, are varied. Some come to opioid use as a way to relieve pain
from surgery, cancer, or other physical ailments (Moryl et al., 2017; Yorkgitis & Brat,
2018). Of those, some come to abuse opioids as a way to supplement their pain
management that they believe is not being properly controlled. For some, opioids are a
natural progression from less potent drugs. Others use opiates as a recreational
experience, merely trying it out due to shear curiosity and to feel the sedating effects of
the drug. As will be examined further, others use opiates for the relief of mental anguish
and trauma (Stumbo et al., 2017).
Opioid Use Disorder
In the years from 1999-2015, the United States witnessed a four-fold increase in
both the overdose deaths from opioids and heroin with a total of 33,091 deaths (Dowell,
Arias, Kochanek, & al, 2017; O’Donnell et al., 2017). Opioid related deaths now account
for the largest number of accidental deaths. While methadone related deaths since 2008
have decreased, there has been an increase in deaths related to heroin, illicitly
manufactured Fentanyl, and abuse of other synthetic opioids (Rudd et al., 2016). An
increase in the prescribing of opioids over the past 15-20 years has contributed to
increasing rates of addiction and mortality due to nonmedical use of prescription opioids.
There is also strong evidence that the nonmedical use of prescription opioids is often
followed by the use of heroin (Compton et al., 2016).
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As of 2013, taking into account health insurance costs, loss of life and thus
productivity, substance abuse treatment, and criminal justice costs, researchers at the
Centers for Disease Control (CDC) estimate the U.S. economic burden to be
approximately $78.5 billion (Florence et al., 2016). We can only assume that as the
opioid mortality rate continues to increase, so will this estimate.
The Diagnostic and Statistical Manual of Mental Disorders fifth edition (5th ed.;
DSM–5; American Psychiatric Association [APA], 2013)1 describes Opioid Use Disorder
(OUD) as a persistent, chronic, use of opioids that over the course of a 12-month period
is characterized by at least two criteria (Appendix B).
Concurrent with the DSM-V criteria, the American Society of Addiction
Medicine (ASAM) describes any addiction in terms of the chronic nature in which these
occur. ASAM further views the brain and neural network as the chief contributor to
addiction as the brain has the inherent capacity to influence motivation, reward, craving,
and need to satisfy both physical and mental discomfort (American Society of Addiction
Medicine, 2015).
Treatment Options in Opioid Use Disorder
Treatment for OUD presently exists in two major forms. These are abstinencebased models and models that include Medication Treatment (MT).
Abstinence Model of Opioid Treatment
Abstinence models are based solely on the idea that people will recover from
opioid use without the assistance of opioid agonists or partial agonists. The colloquial
term often used is that the person withdrew from opioids ‘going cold turkey’. If this
course of treatment is decided upon, the ASAM recommends that some medication be

1

Diagnostic and Statistical Manual of Mental Disorders : DSM-5. (2013) (see Appendix B)
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used to treat withdrawal symptoms and that this is done in conjunction with personalized,
psychosocial treatment. Abstinence based treatment is not the recommended treatment
based on evidence-based practice and current research findings that using Medically
Assisted Treatment is not only safer, but reduces relapse and mortality among other
outcomes (American Society of Addiction Medicine, 2015; Bart, 2012).
Medication Treatment
Medication treatment (MT) is a course of treatment that began when those with an
Opioid Use Disorder were first given medicine in the form of an opioid agonist to help
prevent relapse and relieve the immense symptoms felt when withdrawing from opioids.
This was first initiated with the use of morphine and decreasing doses of heroin to taper
people off of opioids. Pharmaceutical oxycodone, codeine, and Demerol were also tried
initially, but were disregarded as they tended to still have the sedating effect of short
acting opioids and increased tolerance as their use continued. Methadone, which is the
preferred treatment modality with the highest rates of opioid reductions, decreased
mortality, and retention in treatment (Substance Abuse and Mental Health Services
Administration, 2018) approved was then developed as a longer acting opioid that did not
cause the euphoria of morphine and heroin, or increase the tolerance as earlier opioids
had, yet still managed to decrease cravings and did not sedate patients as did earlier short
acting opioids (Center for Substance Abuse Treatment, 2012).
Buprenorphine/Naloxone is a recent addition to the options that clinicians have in
terms of treating people using an opioid maintenance treatment. This drug in particular
has the benefit of seeking the same mu receptors as opioids, yet, does not have the same
effect once it is in place as the naloxone aspect is an opioid antagonist and lowers the
potential for the same euphoria and sedating effects of opioids (Center for Substance
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Abuse Treatment, 2012). Buprenorphine has been shown to be a successful medicinal
treatment for OUD in reducing cravings, relapse, and mortality (Ohtani, 2007).
Naltrexone has been available since the late 1960’s but has only seen an increase
in use as a once a month extended-release injectable. This particular form of MT is used
as a non-agonist medicine that blocks opioid substances from entering mu receptor sites
in the brain. The injectable is thus the preferred method of administration as this
prevents the patient from having to remember to take their pill every day, has a greater
half-life, allows for a greater reduction in cravings, is more expensive initially but then
evens out over time, and relates to longer periods of recovery (Substance Abuse and
Mental Health Services Administration, 2016).
While counseling is the preferred treatment concurrent with opioid substitution
treatment, there are still mixed findings in terms of efficacy of counseling treatment. For
instance, Fiellin et al. (2006) found that during a study of Buprenorphine distribution at
single or multiple times per week, that when combined with short or long-term
counseling, there were no differences between groups that suggested either counseling
method had a significant effect on prevention of relapse. Fiellin et al. did note that the
type of counseling was not prescribed and were not tailored to each individual patient.
Similarly, Weiss & Rao (2017) conducted a study that compared treatment for
prescription opioid users who either received opioid drug counseling and those who did
not. Their findings demonstrated that the counseling group was not more successful in
treatment. However, they did note after further analysis of the counseling groups that
those who had a history of heroin use were more successful in the combined
counseling/Buprenorphine than those with a history of heroin use who were not in the
combined group.
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Conversely, Moore et al. (2016) found that Cognitive Behavioral Treatment
(CBT) was a successful approach when combined with physician managed
Buprenorphine treatment for those with prescription opioid use, but not for those who had
used heroin.
Anxiety/OUD
While PTS dominates the focus of today’s psychiatric worldview, PTS is only one
disorder grouped under the umbrella of Anxiety disorders which is grouped in the AXIS
1 domain of the DSM-V. The AXIS 1 delineation denotes that all disorders in this group
are the most common psychiatric disorders in our culture (DSM-5., 2013).
An 2009 systematic review by Fatséas, Denis, Lavie, & Auriacombe (2010) using
DSM-IV criteria revealed a lifetime prevalence of anxiety among those with an OUD
ranging from 26%-35%. Fatseas et al. (2010) note that of these studies, there are two
major hypotheses for anxiety to present as a diagnosis. When an anxiety diagnosis
emerges initially then is followed by a diagnosis of OUD, often opioids or other
substances are used to self-medicate to relieve the symptoms and feelings or anxiety. In
the contrary sequence, OUD emerges as the first diagnosis with anxiety following as the
second diagnosis as a resultant symptom of being in opioid withdrawal through recovery.
Researchers investigating the prevalence of co-occurring psychiatric diagnoses
among those with an initial OUD diagnosis in Spain, found that anxiety was the highest
co-occurring disorder (53%) (Roncero et al., 2016). Other research examining the
consequences of anxiety on co-occurring diagnoses found that individuals with an
anxiety disorder are more likely to seek out prescription opioids. In a study reviewing
medical office prescriptions for Schedule II opioids from 1995-2010, those with an
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anxiety disorder were 11 times more likely (OR=10.99) to use prescription opioids
(Olfson, Wang, Iza, Crystal, & Blanco, 2013).
Treatment of Co-occurring Anxiety and OUD
Treating co-occurring anxiety and OUD medically presents problems for the
clinician looking to quell both anxiety and OUD cravings as well as other symptoms.
General treatment recommendations for anxiety is to try first-line medications that
include serotonin reuptake inhibitors (SRI) first. These do not always work well in this
population and it is therefore recommended to try benzodiazepines (BZD) as a second
line medication. This approach is typically affective at decreasing symptoms. The
problem is that BZDs are not recommended for use for people with SUDs, especially
OUD (Craske & Bystritsky, 2017).
That recommendation appears to be followed by the majority of physicians. In a
recent study of people using BZDs, only 27.8% of them received them from their
physician (not all were in opioid treatment), while 51.3% bought them on the street and
the remaining 20.9% took them from or were given them by a friend or family member.
If those with an OUD are misusing and abusing BZDs as well, it is clear that it may not
be under the care of a physician (Stein, Anderson, Kenney, & Bailey, 2017).
An earlier synthesis of 200 articles conducted by Jones, Mogali, & Comer (2012)
found a multitude of complications resulting from concurrent use of both opioids and
BZDs. They noted increased use of BZDs for heroin users entering treatment and up to
75% prevalence rate of using BZDs for those in opioid treatment using buprenorphine.
This is supported by a recent study by Morley, Ferris, Winstock, & Lynskey (2017)
examining misuse and abuse of prescription opioids. Utilizing the Global Use Survey,
containing data from several nations, they held country of residence constant in their
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model and were able to determine that those using illicit opioids as well as BZDs had an
OR=6.49 of abusing their prescribed opioid analgesic.
One promising outlook is that the treatment for OUD may in fact decrease
symptoms of anxiety. Ahmadi & Jahromi (2017) hypothesized that one dose of
buprenorphine would decrease anxiety in opioid dependent patients. Here we can see
that OUD was not even the focus, lessening anxiety was the aim. They found that
regardless of dosage amount, using one dose of buprenorphine lessened anxiety
significantly over a seven day period. This study did not address what place anxiety had
within the realm of OUD. They were not asking whether or not anxiety was an
antecedent to OUD, a consequence of OUD, or influenced the outcomes of treatment for
OUD.
Post-Traumatic Stress
Post-Traumatic Stress (PTS) is the consequence of having experienced an
overwhelming physical or emotional event or events that causes the body and mind to
later react as though it were under the same stressors of the initial event or cumulative
events. Both the trauma itself and the symptoms that follow from PTS are highly
subjective. What one person perceives as a traumatic event, may not be the same for
another person. Additionally, after experiencing the same event and being traumatized
by it, people will react to it and exhibit different symptoms from one another. Symptoms
can include but are not limited to: anxiety, social withdrawal, depression, avoidance of
feelings, tremors, flashbacks, gastrointestinal disturbances, somatic pain and discomfort,
etc. (Regel & Joseph, 2010).
Noted trauma psychiatrist and researcher, Bessel Van Der Kolk (2014), states that
recovery for victims of trauma is difficult as the trauma itself often changes features
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within the brain and specifically the pre-frontal cortex. This area of the brain is essential
to making decisions needed to making decisions, plan, and make corrections in behavior.
Trauma Leading to PTSD
Not all traumatic experiences (TE) are created equal and not all who experience
TEs have the same outcome. Experiencing at least one TE is actually a relatively
common experience for people around the globe with one study showing up to 66.5% of
participants meeting criteria for at least one TE in their lifetime (Elhai et al., 2012). Why
some people then suffer from Post-Traumatic Stress (PTS) while others do not is a
question that many are attempting to answer.
Noting a lack of definitive evidence for predictability of PTSD following TE, a
group of international scholars has developed one promising method aimed at
determining predictors of Post-Traumatic Stress Disorder (PTSD) among those who have
had a TE. The researchers utilized data from the World Health Organization’s (WHO)
World Health Survey. Of the 126,096 respondents, 42,634 reported at least one TE over
their lifetime. Exploratory factor analysis narrowed the 29 subtypes of TEs down to 5
factors: “exposure to organized violence, participation in organized violence,
interpersonal violence, sexual-relationship violence, and other life-threatening TEs”
(Kessler et al., 2014, p. 267).
Applying regression modeling and machine learning algorithms allowed the
group to predict that the highest risk for developing PTSD was a TE involving sexualrelationship violence. This type of TE accounted for 12.1% of the overall TEs in the
population but accounted for 32.9% of the overall proportion of PTSD among the group.
The 2nd highest sub-group was a sixth category named Network Traumatic Experiences
which included: unexpected death of a loved one, life-threatening illness of child, other
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traumatic experience of loved one. This accounted for 22.5% of all TEs and 29.7% of the
proportion of PTSD (Kessler et al., 2014). What is striking is that participating in
organized violence such as combat, purposely/accidently caused a death, witnessed death,
etc., accounted for 21.3% of the TEs, yet only 11.2% of the proportion of PTSD. As
expected from previous studies, Kessler et al. (2014) also determined that TE was related
to an increased risk of a psychiatric diagnoses; individuals with TE were 27 times more
likely to have a PTSD diagnosis and just over two times more likely to have a diagnoisis
of generalized anxiety disorder.
For those with prior or current psychiatric diagnoses and a TE, PTSD is more
predictable (Powers et al., 2014). While examining predictability of PTSD for patients
admitted to a level I trauma center, they were able to predict PTSD with 76.3% accuracy
at 3-month follow-up. Powers et al. (2014) found their predictors to be age (younger),
gunshot wounds, and number of premorbid psychiatric conditions. Two critiques of this
study is that they were focused soley on physical injury and negated sexual violence as a
physical injury and thus it was not included in their model. Additionally, during their
screening process, 12% of participants tested positive for drugs and were also given the
AUDIT-C as an alcohol screening. The drugs finding was not included in their model.
Though they included alcohol and found it to be not predictive of PTSD. However, the
inclusion of premorbid psychiatric conditions continues to represent a major predictor for
each study reviewed.
Furthermore, Carlson, Palmieri, & Spain (2017) working on the predictability of
PTSD as well, found another set of risk factors following trauma to be predictive of
PTSD. These were negative thoughts, post-trauma life stress, post-trauma social
constraints, post-trauma social support, acute stress symptoms, and childhood home life.
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When these risk factors were subjected to sensitivity and specificity analysis, they found
a high sensitivity or the probability that the risk factors are present in those that have
PTSD (0.85 - 0.97). The specficify or the probability that risk factors were not present in
the people that did not have PTSD was also acceptable (0.68 – 0.83) (Rosner, 2015).
From Trauma Experience to PTSD Diagnosis
While research is promising in terms of how TEs contribute to PTSD, the
importance should be placed on how clinicians are utilizing the aforementioned research
in identifying risk factors, screening, and then diagnosing properly. Liebschutz et al.
(2007) conducted a study at an urban primary care office screening 509 patients for TEs,
PTSD, and psychiatric comorbidities and then compared those findings to the electronic
medical record (EMR) for each participant for diagnostic comparison. Consistent with
Elhai et al. (2012) they found that 79% of the participants had at least one TE and 65%
had more than one TE. They determined that 39% met the DSM-IV criteria for lifetime
PTSD and 23% met the criteria for current PTSD. Consistent with previous studies
(Carlson et al., 2017; Olaya et al., 2015; Powers et al., 2014) was the finding that 91% of
those with PTSD had at least one co-morbidity.
Of these participants, 64% of those with anxiety, had a lifetime PTSD diagnosis,
42% had a current diagnosis of PTSD. Those with substance use had a lifetime PTSD
prevalence of 52%. The most alarming finding of the study is that when comparing these
findings to the participant’s EMR, they found that only 11% of those with PTSD had a
congruent diagnosis reflected in their EMR. In a recent review (Greene, Neria, & Gross,
2016) of studies examining the prevalence of PTSD in primary care settings, prevalence
rates in studies ranged from 2 - 27% and detection rates from 2.4 – 46.5% when
comparing study diagnosis with EMR similar to Liebschutz et al. (2007).
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Opioid Use Disorder and Post-Traumatic Stress
Survivors of trauma, looking for a way to cope, use opioids or other drugs and
alcohol to self-medicate (Hser, Evans, Grella, Ling, & Anglin, 2015a). However,
Henwood & Padgett (2007) remind readers that the purely self-medication hypothesis is
one that should be viewed as suspect and may include multiple risk factors and comorbidities. Trauma is often an antecedent to the use of opioids. Utilizing data from the
National Epidemiologic Survey on Alcohol and Related Conditions III, Hassan, Foll,
Imtiaz, & Rehm (2017) demonstrated that individuals with a PTS diagnosis earlier in life
were three times as likely to develop an OUD compared to those who had an OUD but
were never diagnosed with PTS. Controlling for age, education, marital status, living
area, self-reported general health, and employment status still resulted in a 65% increase
in risk.
One of the reasons PTS is detrimental to those with an OUD is the increased
capacity for misuse of the opioids they receive. Cochran, Hruschak, Bacci, Hohmeier, &
Tarter (2017) performed latent class analysis on data from 333 people in community
pharmacies specifically looking for subgroups that may be more predisposed to using
prescription opioids improperly. One subgroup identified was a group of individuals with
co-occurring PTS, depression, and report of pain in the past four weeks. Among this
group, 44% had misused their prescription opioids and were six times more likely to do
so than other groups identified.
Symptoms of PTS with OUD
Even the degree to which symptoms of PTS are experienced are affected by
having a co-occurring OUD. Meier et al. (2014) found that the symptoms of PTS were
influenced by overall substance use and even more by opioid use. Of their sample of 573
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subjects, they found that of the 218 people using prescription opioids, 47% met the
diagnostic criteria for PTS. They were also able to determine that symptom severity
increased with polysubstance abuse and increased depending on substances.
Increased PTS symptom severity and increased substance use disorder (SUD) was
also demonstrated in an much earlier study conducted by Brown, Stout, & GannonRowley (1998) on the perception of the relationship of a person’s own substance use
disorder (SUD) and their co-occurring PTS or trauma symptoms. They determined that
people with co-occurring SUD/PTS tended to view these two disorders as related to one
another. Though a small sample, 77% of their participants felt that when their trauma
symptoms worsened, there was a direct impact on their substance use. Similarly, 78%
responded that if their trauma symptoms resolved or improved, so did their substance use.
Treatment of OUD with Co-occurring PTS
Treatment of opioid use disorder (OUD) while co-occurring with PTS is
complicated and may require multiple frameworks. Beyond the reasons for why one uses
opioids, or the inherent diversity in the demographics of people who use opioids, Killeen,
Back, & Brady (2015) provide a review of the mix of obstacles that impacts treatment of
both PTS/OUD together and individually. One key barrier to treatment is that at times
there is a lack of commitment to treat both OUD and PTS equally or concurrently. This
is compounded often by an organization’s misunderstanding of a particular paradigm and
lack of a method to ensure fidelity to the prescribed treatment of concurrent OUD/PTS.
In some parts of the country, counselor turnover is high due to a perceived stigma of
treating patients with SUD while simultaneously valuing the treatment of those with PTS.
Just these issues alone make it difficult to provide a sustained, evidence-based treatment.
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Thus, co-occurring Post-Traumatic Stress Disorder (PTS) can result in reduced treatment
outcomes than for patients without symptoms of PTS (Meier et al., 2014).
However, there have been instances where sustained OUD/PTS treatment has
been shown to be effective. Tofighi et al. (2015) found that due to early treatment
evaluations at admission to a buprenorphine clinic, they were able to treat PTS
concurrently with OUD. They evaluated treatment outcomes for subjects who were in
concurrent OUD treatment and were participating in psychiatric treatment for their PTS
both pre and post Hurricane Sandy. They noted that although subjects missed follow-up
appointments and missed opportunities to acquire their buprenorphine, at 6-months post
Hurricane Sandy, this particular group showed no increase in positive drug screens.
Peirce, Brooner, King, & Kidorf (2016) evaluated subjects who had an alarming
average of 18 lifetime traumatic events. They found that when subjects had a traumatic
event during treatment, this doubled their risk of non-compliance with treatment in the
month following the event. Even more profound was in the months after the initial
month, this risk doubled again.
Stress Response in OUD/PTSD
The reciprocal relationship between withdrawing from opioids and an increased
stress response is problematic for those with OUD. While withdrawing from opioids
increases stress, the converse is also true that those with OUD use opioids to reduce
stress. Constantinou et al. (2010) compared the stress levels and attentional bias of users
of heroin against ex-users and non-users. The current users of heroin demonstrated not
only a significantly higher level of stress during the study than ex-users and non-users,
but also had significantly higher levels of drug craving during the study. An additional
finding of the study was that the current user group had a significantly higher level of
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attentional bias during short and long-term exposure to toward heroin related subject
matter utilized during the study. They posit that stress potentially leads to more
attentional bias and craving in users which directly relates to an inability to resist and
remain abstinent. This is reflective of Lazarus & Folkman’s (1984) concept of appraisal
within stress and coping. As a current user is appraising a stressful situation or event, if
attentional bias is focused on the use of an opioid, this attention limits the ability to cope
and reduce stress, thus leading potentially to the use of an opiate.
Withdrawing from opioids can cause large amounts of stress. Therefore,
refraining from opioid use while withdrawing can be extremely challenging and stressful.
This can often lead to increased use (Danovitch, 2016; Hassan et al., 2017).
Demographic Differences in Treatment of OUD/PTS
Gender
It should be noted that women are at greater risk of experiencing trauma through
sexual violence, emotional and physical abuse, and at younger age. There are marked
gender differences within OUD both for patients with and without PTS. PTS also has a
role in partially mediating the relationship of women’s substance use with violent
offending (Howard et al., 2017). As women with PTS continue to use substances and
commit violence, they are as a consequence, more likely to have a history of
incarceration (Komarovskaya et al., 2011). In a study of 573 adult subjects, Meier et al.
(2014) demonstrated that women who have PTS and OUD not only experience almost
three times the severity of PTS symptoms as men, but also 30.1% of the women in the
sample compared to 18% of the men had co-occurring PTS and OUD.
While there has been variation in outcomes for those in concurrent treatment for
SUD and PTS, there has been significant improvements for those receiving trauma
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focused dual treatment with attrition rates being the same across all groups (Killeen et al.,
2015). Clinicians agree that there is a need for concurrent treatment, however are not in
agreement as to how treatment should progress, especially in cases of severe trauma. The
concern is notably whether or not the person re-experiences trauma during treatment and
thus desires to re-abuse substances to relieve said trauma (L. M. Najavits et al., 2011).
OUD among Persons with an Involvement in the CJS
Having an involvement in the Criminal Justice System (CJS) has the potential to
increase the risk of traumatic experiences and thus PTS (Anderson, Geier, & Cahill,
2016; Harner, Budescu, Gillihan, Riley, & Foa, 2015; Kouyoumdjian et al., 2015).
Additionally, entering the penal system in the United States while suffering with an OUD
can further exacerbate an already difficult situation. Incarceration presents one of
several situations and depends whether that person is incarcerated in a federal prison or a
state run correctional facility.
OUD in Federal Prison
The United States Bureau of Prisons (BOP) publishes a clinical treatment manual
that directs clinicians within the federal prison system on a prescribed method for
detoxification of inmates who present with a current SUD. This manual has not been
updated since 2014 (Federal Bureau of Prisons, 2014). The manual follows a theoretical
framework of abstinence from opioids and provides little instruction on how to achieve
this within 5-10 days.
If medical based treatment is provided, the recommended course of treatment is
the use of Methadone until the cessation of withdrawal symptoms, followed by a 10%
taper daily until the Methadone is discontinued. Typically, adjunct treatment is included
only for withdrawal symptoms in the form of Clonidine, as well as anti-inflammatories,
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antipyretics, anti-emetics, and anti-anxiety medication, but not a long-term opioid
maintenance MT. In fact, the document states if an inmate enters with a current
Buprenorphine use, they are to be detoxified of it and then discontinued.
In addition, the Health Services division of the BOP releases a pharmaceutical
formulary document that describes what the pharmacies in federal prisons will have on
hand and what they are allowed to dispense and for what reasons. In regards to the use of
Buprenorphine, the document reads, “will only be approved for detoxification, [NOT] for
pain or maintenance treatment” (Federal Bureau of Prisons Health Services, 2016, p.17).
Allowing Buprenorphine for a period of detoxification may allow for a controlled
withdrawal and symptom management, however does not assist long-term recovery
during their incarceration or after re-entry (Hser et al., 2015b). This is especially
important for those using heroin, as it has been demonstrated that abstinence episodes last
longer each successive time and are more effective when accompanied by sustained longterm MT (Nosyk, Anglin, Brecht, Lima, & Hser, 2013). It should also be noted that the
BOP manual lacks any reference to a counseling or therapeutic model that an inmate may
utilize in the recovery.
OUD in State Correctional Facilities
Each state has their own policy regarding the use of MT within the correctional
system. In some states, correctional facilities provide MT maintenance, while others do
not. Rikers Island Correctional Facility (Rikers) in New York is one facility that has
treated their inmates who present with OUD with MT, more specifically Methadone since
as early as 1987. While in other facilities an inmate is provided no medical treatment for
opioid withdrawal (Aronowitz & Laurent, 2016).
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Besides ignoring the ethical imperative to humanely treat individuals and provide
autonomy in healthcare decisions (Ludwig & Peters, 2014; Wakeman, 2017), not
providing an MT at the beginning of incarceration has long-term implications for
increased mortality and suicidality in the first few weeks of the incarceration experience
(Gisev et al., 2015; Larney et al., 2014; Rivlin et al., 2013). A report authored by the
Public Health Department of Massachusetts, noted greater than 50% risk of mortality
when comparing the opioid deaths of former inmates (869.4/100,000 people) in the state
to non-inmate opioid deaths in the state (15.4/100,000 people) (Massachusetts
Department of Public Health, 2016).
As noted in the prior section, treatment with continued opioid maintenance
agonists or antagonists, is still not prevalent within the U.S. correctional system even
though these methods are effective evidence-based medical practices. There are
instances where this is occurring and confirming that this a successful, viable treatment
methodology for incarcerated populations with an OUD.
Treating inmates during their incarceration has lasting effects during the
incarceration experience as well as post-release. Rich et al., (2015) performed a
randomized controlled trial involving inmates in a Rhode Island correctional facility.
These inmates were randomly assigned to one of two groups upon admission: one a
Methadone forced withdrawal group (the current practice in those facilities), and the
second, a Methadone continuation group. The findings are supportive of other studies.
The continuation group was more likely to seek out and follow-up with Methadone
treatment post-incarceration. One striking difference from other studies in regard to
mortality, was that the one opioid related death post-release was from the continuation
group. Finally, in another small sample feasibility study, buprenorphine treatment
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initiated while incarcerated was related to continued treatment after release (Zaller et al.,
2013).
Persons with an Involvement in the CJS and MT
Exiting the correctional system with an OUD significantly puts individuals at
higher risk for increased morbidity and mortality as well as re-incarceration (Binswanger
et al., 2016; Marsden et al., 2017; Merrall et al., 2010). The risk is higher for younger
people, women more specifically. In a study of 42,015 recently released individuals,
14,920 of which were young prisoners (<25yr), Van Dooren, Kinner, & Forsyth (2013)
determined that the younger group was less at risk for mortality than older, previously
incarcerated individuals. However, poisoning by drugs was the leading cause of death
for the younger group with men at 43% and women 50%. In this sample, younger
individuals were six times more likely to die than their community peers; younger
women were 20 times more likely to die.
Treating those with OUD at the beginning of their incarceration with MT has
been demonstrated to significantly affect their health, mortality, and re-offending postrelease. Researchers for the Australian government compiled four sets of data pertaining
to mortality, re-entry of prisoners, addiction, and a general offender database (Gisev et
al., 2015). One significant finding was that initiating MT at the entry to incarceration
resulted in a 93% reduction in unnatural deaths (drug overdose) within the first four
weeks of post-release. Combining records of post-release mortality, re-entry, and MT
continuation, Gisev et al. further determined that drug use accounted for death the most.
Examining post-release differences between those in MT and those not in MT, those in
MT had the smallest crude mortality rate (CMR) at 6.4 per 1,000-person years and those
not in MT had a CMR of 36.7 per 1,000 person years.
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Likewise, Marsden et al. (2017), found that initiating MT upon release also had a
similar effect. Utilizing a prospective cohort of 15,141 subjects across 32 British
National correctional facilities, they found a significant relationship between initiating
MT upon release and a decline in mortality. With 18 drug related deaths within the first
four weeks post-release, only three were found to be within the group currently
prescribed MT.
Degenhardt et al. (2014), demonstrated similar findings with a cohort of 16,453
people who had a total of 60,101 prison releases over a period of 12 years. Half of this
group was given MT upon release. Of the 1050 deaths that occurred, 135 (13%)
happened within the first 4 four weeks. They found that exposure to MT in the form of
opioid substitution, limited the death rate by 78% for those re-entering prisoners within
the first month of re-entry.
One possible way to mitigate these issues is to have the incarcerated population
with a dependence on opioids, initiate MT upon arrival. While MT has been shown to be
successful as a treatment modality for incarcerated prisoners evidenced by a lower
recidivism rate, a decrease in cravings for opioids, and lower rates of sexually transmitted
infections (Aronowitz & Laurent, 2016), understanding the effect that PTS will have on
the relationship of MT and having a history of incarceration, will allow clinicians to treat
those who suffer from OUD and PTS more effectively. Since MT has not become
commonplace in incarcerated settings, few studies have examined MT in the prison
setting (Hedrich et al., 2012).
Of the few studies related to describing the outcomes of MT on incarcerated
individuals both in the correctional setting and upon re-entering the community, initiating
MT while incarcerated has been found to have significant effects on re-incarceration after
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having re-entered the community. Larney, Toson, Burns, & Dolan (2012), utilized a
random control trial to assess MT in incarcerated men who inject heroin. The researchers
found that while overall, initiating MT pre-release, did not significantly reduce reincarceration. However, those that stayed in the prescribed MT after release reduced their
re-incarceration risk by 20%. In contrast, while Gordon et al. (2017) demonstrated a
longer period of time in treatment for those initiating Buprenorphine pre-release vs. those
starting post-release, they did not demonstrate a significant difference in relation to using
opioids post-release and re-incarceration. This may be attributed to a lack of linking
patients to treatment, monitoring subjects closely, and a short time period of induction to
dosing of only 3-6 months pre-release (Vocci et al., 2015). In addition, there was
insufficient study power and there was not a true control group of a re-entered people not
taking MT.
Buprenorphine appears to be favored by those with and OUD that are incarcerated
when compared to methadone. When treatment was initiated during incarceration using
either buprenorphine or methadone, individuals preferred buprenorphine (Awgu, Magura,
& Rosenblum, 2010) and subjects further stated that they would be more willing to use
buprenorphine post-release. This preference for buprenorphine was based on subject
responses that buprenorphine was more effective, presented less side effects, reduced
cravings more than methadone, and that it took effect quicker. In an additional study,
those subjects treated with buprenorphine pre-release were more likely to continue to
arrive for their appointments at a community treatment center more than the methadone
treatment group. They also found that 5 of their methadone group switched post-release
and switched from the methadone treatment to the buprenorphine group (Magura et al.,
2009). This preference for remaining in treatment and a greater affinity for
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buprenorphine may be related to concern on the part of the subjects to limit withdrawal
from methadone, and a more effective response.
Many studies have primarily focused on re-incarceration, mortality, and treatment
continuation as general outcomes (Hedrich et al., 2012). Outcomes such as cravings,
relapses, retention of employment, and co-occurring PTS symptoms, should be
considered to further understand the implications of starting MT programs in more jails
and prisons.
Gender Differences in MT during Incarceration
The literature examining the impact of MT during incarceration has identified
some difference based on gender. For example, Farrell & Marsden (2008) found that
women had a risk of mortality that was 10 times greater than men in the first week of
release from prison and only dropped to 8 times greater at 52 weeks post-release. When
women initiated treatment with buprenorphine while incarcerated, Gordon et al. (2017)
determined that women were more likely to resist using opioids for a greater length of
time than their male cohort, suggesting that if more women were treated while
incarcerated, there may be the opportunity to decrease mortality post-release.
Persons with a History of Incarceration and PTS
Of the 20.5 million with a Substance Use Disorder (SUD), approximately 1.4
million are currently incarcerated individuals (Fox, 2015). Of those prisoners,
approximately 40% report having Post-Traumatic Stress (Flatt et al., 2016). This is
especially true for both men and women entering incarcerated settings have also been
shown to have higher rates of childhood trauma (Giarratano, Ford, & Nochajski, 2017).
Those who were exposed to trauma before incarceration also show an increase of trauma
symptoms while incarcerated (Schappell et al., 2016).
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Diagnosis of PTS within the penal system is laden with issues and leads to
inaccuracies in terms of who is and is not diagnosed with PTS. Depending on the prison,
some provide a self-report questionnaire to ascertain whether or not this person has been
diagnosed with PTS or experiences symptoms of PTS (Beck et al., 2013). This leads to
problems when people who over report diagnoses with PTS require additional resources
and care, while some who have not been formally diagnosed yet experience symptoms of
PTS and often underreport these symptoms (Oguntoye & Bursztajn, 2009).
Reporting on the diagnosis of 201 women prisoners with or without PTS, Warren,
Loper, & Komarovskaya (2009), found that 97% experienced some type of trauma in
their life and those who met the diagnostic criteria for PTSD reported 6.6 trauma
experiences, compared to 4.8 experiences for those who did not meet criteria. While
there was a variety of traumas experienced, they determined that it was the cumulative
number of traumas that appeared contribute to a diagnosis of PTSD, not trauma type.
Warren et al. (2009) pointed out that symptoms of PTS often occur with other
diagnoses or without a specific diagnosis and warn against diagnosing inmates just from
a report of symptoms. It should be noted that these women also felt that experiencing a
trauma such as a mugging, rape, or physical abuse, described these experiences as being
as traumatic to them as witnessing an act of violence towards another person. This is
closely supported by Swopes, Davis, & Scholl (2017) who reported finding that the
incarcerated women in their study rated witnessing an act of violence third behind being
assaulted with a deadly weapon and unwanted sexual contact before the age of 13. They
also found that women rated witnessing trauma more traumatic than unwanted sexual
contact before the age of 18 and being attacked without a weapon.
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For women with PTS and also being incarcerated, witnessing trauma is likely and
therefore concerning as this has implications to expose inmates to further trauma while
incarcerated (Beck et al., 2013; Hagan et al., 2017). People who have been incarcerated
or are presently incarcerated often feel unsafe, exhibit increased anti-social behavior, and
symptoms of trauma due to circumstances related to, but not limited to, childhood
trauma, domestic violence, and military violence pre-incarceration (Schappell et al.,
2016).
Re-entry Into the Community with PTS
Experiences before, during, and after incarceration all contribute to individual
levels of levels of PTS. Schappell et al. (2016) assessed the trauma symptoms of 100
men who had previously been incarcerated. Being victimized during incarceration
demonstrated a significant relationship to higher levels of PTS. Having a mental health
issue prior to incarceration was also found to moderate the severity of victimization and
thus PTS. Men that re-entered their communities but did not live in a half-way house or
with family experienced the highest amount of PTS. Remarkably, of the 100 men in the
study, only 11 stated that they had not witnessed or been the victim of violence while
incarcerated.
Results from an epidemiologic study of 5008 people by Anderson, Geier, &
Cahill (2016) confirm similar findings to Shappell et al. (2016) that having more
traumatic life events was related to an increase in having a history of incarceration. This
study also examined trauma type. Being in a car accident was one of the weaker
predictors of incarceration (AOR=1.7), while being physically beaten was the strongest
predictor (AOR=3.5). Having a trauma experience that potentially would potentially lead
to death resulted in a three time increase in the likelihood of incarceration. Shappell et al.
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also found that individuals with a lifetime diagnosis of PTSD were twice as likely to be
incarcerated than those without PTSD. Limiting further trauma experiences and linking
to treatment post-release is imperative to reducing not only further opioid use, but further
involvement with the criminal justice system.
While PTS itself if is a risk factor for increased incarceration, this is especially
evident for black men. Having PTS increases the odds of being arrested, jailed,
imprisoned, and having experienced at least four or more incidents of trauma (Jäggi et al.,
2016). Anderson, Geier, & Cahill (2016) demonstrated that incarcerated black men also
were at greater risk for PTS than their peers who had did not have a history of
incarceration.
Gender Differences of PTS and Incarceration
While 18% of the overall incarcerated population will present with some mental
health diagnosis, gender differences are also present. Women are more likely to be
diagnosed with post-traumatic stress, substance abuse, and depression (Al-Rousan et al.,
2017). Incarcerated women with PTS have experienced trauma in a variety of ways
before entering jail or prison. This ranges from unwanted sexual contact from a young
age, witnessing acts of violence toward others or animals, torture, and physical assault
(Harner et al., 2015). While Giarratano et al. (2017) found there to be no significant
gender differences in terms of the occurrence of behavioral problems associated with PTS
between male and female inmates, women displayed more PTS symptoms compared to
men as well as a greater risk of use of heroin or cocaine. Men with PTS have been noted
to seek out after-care treatment post release for their PTSS more than men without PTS
(Kubiak, 2004). An explanation for this could be that they were victimized during
incarceration that they did not face previously in the community. Since women have
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historically been victims of trauma pre-incarceration more than men, release to the
community where they have previously experienced trauma may contribute to greater
relapse and further exacerbating PTS.
Persons with an Involvement in the CJS, PTS, and OUD
As demonstrated earlier, PTS and OUD combined, as well as incarceration and
OUD combined, have the potential to seriously disrupt individual and public health.
Results are mixed in regard to studies that include incarceration or a history of
incarceration, mental illness, and opioid use. This could present challenging treatment
issues for incarcerated populations with PTS that are re-experiencing trauma or living
through initial trauma while incarcerated and then later treated for OUD after release. As
this is a group that may not be receiving psychiatric treatment while incarcerated as well
as not receiving MT, it is possible that this population would be tough to recruit to
treatment as well as maintain compliance with treatment protocols.
For instance, Swopes, Davis, & Scholl (2017) struggled to find between-group
differences in their dual treatment of women experiencing co-occurring PTS/OUD while
incarcerated. While the women in the study were able to decrease cognitions of PTS
post-treatment, there was not a significant between-groups interaction that showed
marked differences.
Greenberg & Rosenheck (2014) found a significant relationship between mental
health, substance use, and re-incarceration. They determined that while race/ethnicity
and recent immigration did not present a greater risk for a history of incarceration, being
male, not having finished high school, and being young were positively associated with
having and incarceration history. They also determined that those with a SUD were at
greater risk for longer incarcerations.
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Robertson et al. (2018) compared the use of methadone, buprenorphine, and
naltrexone for those with an OUD, mental illness diagnosis and involvement to some
extant in the criminal justice system. Their results showed only a 3% risk in the
incarceration rate for those being treated with buprenorphine compared to the comparison
group. However, the methadone and naltrexone groups showed a 39% and 62% greater
risk of incarceration respectively.
Functional status/outcomes (Substance Abuse and Mental Health Services
Administration, 2012) are still not prevalent measures in follow-up studies with this
particular sub-group. For instance, Zlotnick, Johnson, & Najavits (2009) studied
PTS/SUD treatment outcomes while utilizing a cognitive behavioral treatment developed
by Najavits (2002) called Seeking Safety. Using a randomized control trial of treatment
with Seeking Safety compared to treatment as usual, they studied a sample of women
recently incarcerated who had co-occurring PTS/SUD. Although appearing
underpowered in their sample size of n=49, they employed common measures including
addiction assessment tools and self-reports of treatment satisfaction, and re-incarceration
(the only functional status outcome). They did determine that 22% of those in the
treatment group returned to prison within 6 months, compared to 45% in the nontreatment group.
Racial Differences in Incarceration, PTS, and OUD
While Greenberg & Rosenheck (2014) found that black men had a 13% higher
incarceration rate and found that black men were 2.5 times more likely to have longer
sentences to fulfill. This could pose several problems for black men, but especially black
men that have an OUD. As they stay incarcerated for longer, more than likely without
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treatment, and have the possibility of experiencing more trauma, they are potentially at
greater risk for having a tough recovery after they are released.
Theoretical Framework
To understand the relationships between trauma, coping and outcomes of opioid
treatment, Lazarus and Folkman’s Transactional Stress theory will be applied as a
framework within which to view OUD treatment for patients with potential maladaptive
coping strategies developed while dealing with co-occurring OUD and PTS.
Lazarus and Folkman (1984) situate their Transactional Stress theory within the
framework of people experiencing stress in a myriad of ways throughout their individual
life cycle. While not developed initially for addiction-based contexts, this theory is
especially pertinent to apply to addiction treatment and this particular study. The current
study hypothesizes that stress, in the form of traumatic stress from life experiences and
particularly stress of incarceration is what in effect causes individuals to not only use
opioids in the first place or exacerbates a chronic use, but also restricts them from
recovering in the same manner of those who have not experienced stress in the same
manner.
Stress
The traditional concept of stress is that stress is a stimulus followed simply by a
mental or physiological response. Lazarus and Folkman (1984) reject this concept in
favor of a more fluid and flexible one. This concept of stress is focused on the
relationship between person and environment. Depending on both of these variables, the
confirmation of stress is based on the cognitive appraisal of the specific person and not
people in general. The underlying use of stress theory for Lazarus and Folkman is that

41

individuals possess varying resources and either respond or fail to respond to stress and
traumatic experiences accordingly.
Appraisal
For Lazarus and Folkman (1984), cognitive appraisal is the formation of thoughts
regarding a specific environment or situation based around the idea of well-being and
limiting vulnerability. People appraise events in regard to whether or not the results will
bring them harm or will be beneficial. It should be noted that these appraisals are
ongoing and are not always fully thought out decisions, but cognitively happening at all
moments. They delineate three specific forms of appraisal: irrelevant, benign-positive,
and stressful.
Irrelevant
Irrelevant appraisal is the act of appraising a situation and deciding that this has
no inherent cause for concern or excitement and therefore is disregarded.
Benign-Positive
Appraising an encounter or environment and deciding that this is in fact beneficial
instead of threatening to well-being, would be seen as Benign-Positive.
Stressful
Appraising a situation as stressful includes three potential concepts: fearing some
harmful experience, one that brings a threat, and one that potentially presents a challenge.
Harm can arrive in a multitude of ways i.e. physical, mental, social, or loss of a loved
one. Threatening situations cause stress because they have yet caused harm but have the
potential to do so and this in and of itself creates an anticipatory stress. Challenges can
be both beneficial and harmful. Perceiving a challenge inherently allows us to first think
of the benefit that we can derive from successfully navigating the challenge. However,
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Lazarus and Folkman (1984) point out that challenge and threat can be extremely similar
as a cognitive appraisal. One may see potential benefits from a challenge, but then also
immediately formulate the idea of the threat and vulnerability of not succeeding within
the challenge. Appraisals can also be regarded as time-oriented or successive.
Lazarus and Folkman (1984) consider appraisals of similar situations to be
primary, secondary, and reappraisals. As one continues to reappraise situations, they may
employ more effective coping mechanisms and thus find successful resolutions to
stressful situations. These are indeed meaningful. Instead of a group of automatic
behaviors that are a programmed response.
Coping
Traditionally, coping was identified as the way that people control a situation or
their response to a situation to limit the overall affect it may have on them. Lazarus and
Folkman (1984) define coping as, “constantly changing cognitive and behavioral efforts
to manage specific external and/or internal demands that are appraised as taxing or
exceeding the resources of the person” (p. 141). They chose this definition based on the
premise that this understanding of coping included the ability for the individual to change
within different situations rather than having one trait that automatically gave them a
defined way of responding to the situation. This is a similar concept to resilience.
Mechanism of Theory
Lazarus and Folkman (1984) describe appraisal and coping as mediating
processes. Antecedents of these processes include the person’s sense of control and the
environment in which demands, or harm are perceived. These initiate mediating
processes to be enacted as the person moves through successful iterations of appraising
and then enacts certain coping strategies. The connection between emotion and coping is
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also described by Folkman & Lazarus (1988) as a bi-directional processes. It is not
coping that affects emotion or vice versa. Their view is that one can affect the other in
either direction. Furthermore, Folkman & Lazarus found coping or lack of coping to be a
mediator of emotion in stressful encounters. These lead to immediate effects related to
physiological and psychological changes. This then potentially promotes long-term
effects such as somatic health/illness or positive/negative social functioning. This is
illustrated in Table 1.

Table 1. A theoretical schematization of stress, coping, and adaptation (Lazarus and
Folkman, 1984, p.305).
Causal
Antecedents

Mediating
Processes

Immediate Effects

Long-Term
Effects

Person variables:
values
commitments

Primary appraisal

Physiologic
changes

Somatic
health/illness
Morale (well-being)

Beliefs: sense of
control

Reappraisal

Positive/Negative
feelings

Environment:
situational
demands,
constraints

Secondary appraisal

Coping:
Problem-focused
Emotion-focused
Seeking, obtaining,
and using social
support

Social Functioning

Quality of
encounter outcome

Resources: (e.g.,
social network)
Ambiguity of harm
& imminence of
harm
Relation of Theory to OUD
Managing emotions and employing effective coping strategies has been shown to
provide a protective factor against substance use. Employing a problem-based coping
strategy rather than an emotionally-based coping strategy reduces poor self-efficacy and
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thus allows a person to work through their stressor rather than distance themselves and
use substances as a means of coping (Rabani Bavojdan, Towhidi, & Rahmati, 2011).
Bavojdan et al. (2011) also demonstrated that those who perceived themselves in less
control of their lives and sensing that the external environment was more in control of
them, were more likely to have a substance use disorder (SUD). This has been further
supported by the work of Hassanbeigi, Askari, Hassanbeigi, & Pourmovahed (2013).
Counseling/Training in OUD
Lazarus and Folkman (1984) posit that training a person to first recognize
stressors and appraise them thoughtfully and from a problem-centered framework will
allow them manage emotions and cope more effectively. This is supported by the
Substance Abuse and Mental Health Services Administration (SAMHSA) and the
American Society of Addiction Medicine (ASAM), both of which encourage counseling
as an adjunct to medication treatment (MT) (American Society of Addiction Medicine,
2015; Substance Abuse and Mental Health Services Administration, 2016).
Theoretically speaking, as any person experiences a stressor, they would first
likely appraise that from an emotional point of view. They would then make a second
appraisal which would ideally be derived from a problem-focused viewpoint which
would then inform a decision of how one wants to act in this situation. This is delineated
as both a cognitive decision as well as a physiologic reaction to the stressor. This would
ideally result in a positive long-term adaptation that would allow that person to have a
beneficial or adaptive reaction to that particular stressor that next time it occurred in their
life (Figure 1).
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Antecedent
(Trauma)

1st
Appraisal
(Emotional)

2nd
Appraisal
(Problem
focused)

Decision

Long-term
adaptation

Figure 1. Theory applied to successful coping and appraisal.
Medication Treatment, PTS, and Involvement in the CJS
Using opioids in the setting of experiencing symptoms of post-traumatic stress
represents a lack of coping and appraisal based on the inevitability of harm. To reduce
harm and vulnerability, the individual turns to opioids as a coping strategy. Withdrawing
and not using opioids represents both a threat for the individuals included in MT. The
threat perceived can be viewed in a social or neurobiological context. Socially, the
perceived threat is that one will have to inevitably live among potential stressors without
using opioids as a coping strategy. Neuro-biologically, the individual risks the threat of
not only feeling ill, but also failing to re-establish their normal neurologic state free of
opioids. This study further hypothesizes that for a large set of people in recovery, there
may by multiple instances of relapse due to perceived stress and lacking fundamental
appraisal and coping mechanisms.
Incarceration, as hypothesized in this study, has the potential to be acted upon by
post-traumatic stress. PTS has the potential to generate further stress and a lack of coping
and appraisal upon the person with an incarceration history.
However, as Lazarus and Folkman (1984) remind the reader, threats can also
represent positive challenges. For instance, consider an individual participating in MT at
an addiction treatment center. Upon appraising the outcomes after staying free of drugs,
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one may perceive the inherent benefits of remaining employed, visiting or living with
their children, feeling healthy, and reviving intimate relationships.
Lazarus and Folkman (1984) theorize that the continued appraisal and coping,
will inevitably lead to long-term adaptation and proper management of emotions. Again,
this relates to those within MT. As relapse happens, the general desire is for the length of
time between each relapse to progressively become longer and longer. This can
contribute to recovery in that Lazarus and Folkman’s long-term adaptation allows the
person to continually make re-appraisals that will determine how a person will cope with
their environment and stressor at a later trajectory in their lives. This is demonstrated in
Figure 2.

Antecedent
(Opioid
depenence
and PostTraumatic
Stress)

1st
Appraisal
(potential
for added
stress and
relapse)

2nd
Appraisal
(weighing
opioid use
vs.
abstaining

Continued
medication
treatment

Adaptation
to nonreliance on
opioids

Figure 2. Theory applied to successful coping and appraisal within OUD treatment.
As a person with OUD and PTS are in MT, when they meet a potential stressor
the first action is to appraise this from an emotional viewpoint. They then reappraise this
with a problem-solving framework that allows them to employ coping strategies to
effectively remain drug free and continue with MT. This continuation of MT without the
use of opioids allows them to continue adapting to life without a reliance on opioids.
Theoretical Framework Summary
Lazarus and Folkman’s (1984) Transactional Stress theory as outlined in Stress,
Appraisal, and Coping theorizes that human beings live within an environment that is
inherently stressful for individual reasons. As people navigate this environment, they are
47

continually (consciously or unconsciously) reacting to these stressors. If successfully
experiencing these stressors, people inevitably appraise these situations based mostly
from a problem-solving perspective. They theorize that as people appraise from only an
emotional perspective, they may not make purposeful, coping oriented decisions which
can contribute to maladaptive mental and physical health.
As people in recovery are often experiencing an onslaught of stress on a daily,
sometimes, minute to minute basis, viewing their capacity to appraise situations from the
Transactional Stress model allows us to understand recovery and relapse from an emotion
and problem-solving framework. As people in recovery continue to calm their brain and
thus nervous system with medication treatment, they generate physiologic adaptation to
stress. From here they can also learn to appraise their stressors appropriately from an
emotional viewpoint and then move to an appropriate problem-based strategy to move
themselves forward. The goal is that by moving forward consistently, the person
develops resilience and a long-term adaptation to that stress that would require less and
less dependence on opioids for coping.
Significance of the Study
Opioid addiction can lead to death, criminality, numerous co-morbidities, reincarceration for previously incarcerated individuals, increased exposure to HIV and
hepatitis C, and neonatal abstinence syndrome for newborns (NIDA, 2015). Those with
PTS and a history of incarceration are at greater risk for these outcomes. It is imperative
to understand the relationship of PTS to MT to enable clinicians to intervene more
appropriately and enhance treatment outcomes for those with co-occurring PTS and
participating in MT. Understanding how these interactions will also affect the recovery
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process for those that have been incarcerated and will aid in long term success and
adaptation.
Viewing involvement in the criminal justice system through the lens of Lazarus
and Folkman’s Transactional Stress theory, incarcerated men and women are already
shown to be a greater risk when entering the system with a history of PTS. As this PTS is
exacerbated in an incarceration experience, it is hypothesized in this study, that PTS may
moderate or strengthen the relationship between incarceration and successful OUD
treatment outcomes. Those with PTS and an incarceration history are at even greater risk
for inappropriate appraisals of stress that could potentially become heightened after
leaving prison or jail and entering OUD treatment. Inaccurately appraising situations
from a place of fear and trauma could result in the action to relapse and use substances
once again.
Developing a clearer understanding and framework for treatment within this
subset of the population will allow clinicians to treat other groups of individuals suffering
from the combination of PTS and OUD. Veterans, sexual abuse survivors, refugees, or
other individuals living with PTS and OUD will benefit from the approaches and
practices that can be instituted as a result of the data gathered from this proposed study.
Understanding these relationships more clearly will enable clinicians to intervene more
appropriately when presented with someone with co-occurring PTSD and participating in
MT. Understanding how these interactions affect those with involvement in the criminal
justice system who are in the process of recovery will aid in long term success.
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CHAPTER 3
METHODOLOGY
Methods
This chapter provides on overview of the research methodology that will be
utilized in the proposed study. The chapter ends with a conceptual definition of
variables.
Research Purpose
The purpose of this study is to explore the relationships between post-traumatic
stress (PTS), involvement in the criminal justice system (CJS), and medication treatment
(MT) success in patients identified with an Opioid Use Disorder (OUD).
Research Design
This study will employ a correlational retrospective analysis of Electronic Health
Records (EHR) data.
Electronic Health Record / Retrospective Chart Review
Since the inception of EHR, the ability to utilize these records beyond the scope
of daily patient care and billing purposes has continued to merge into the field of research
as a method to track all patient data for use either prospectively or accessed
retrospectively. The current utilization of EHR is commonly referred to as ‘clinical data
reuse’ or ‘retrospective chart review’. This reuse of data is employed in research realms
such as: epidemiology, genomics, safety, clinical/treatment, and outcomes based research
(Meystre et al., 2017).
Advantages of the EHR Chart Review
There are numerous advantages to EHR chart review. A major benefit of chart
reviews is that they are not as costly as experimental studies that require multiple staff,
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locations, instruments, etc. They are efficient uses of time as one can immediately derive
data from a lengthy time period rather than conducting longitudinal experiments that may
take years to conclude (Gearing, Mian, Barber, & Ickowicz, 2006). Importantly, there
may be instances in research when a researcher does not have the ability to randomize
people for a variety of reasons. EHR chart review is an especially poignant methodology
in these cases (Worster & Haines, 2004).
Disadvantages of the EHR Chart Review
While the benefits of EHR chart review are substantial, there are drawbacks.
Data itself needs to be input into a medical record. This initial input to the record itself
can be suspect due to user error from the standing of the provider (Zozus et al., 2015).
Data abstractors, or those who code and maintain the data, may not always be consistent
and therefore increase the likelihood that data is retrieved in an inconsistent manner
(Polnaszek et al., 2016; Vassar & Holzmann, 2013). Documenting research conducted
using a chart review often does not include a thorough methodology that was utilized
during data abstraction and analysis.
Data Mining EHR
EHR contain data that are either structured or unstructured. This refers to the
classification of data in a manner that is already accessible in a format that can be utilized
immediately for research. Unstructured data refers to data that is in an unclassified
textual format (Meystre et al., 2017).
Advantages of Data Mining
Textual, unstructured data is often found in the form of written notes of
physicians or clinicians, nurses, and other auxiliary care personnel. Extracting this data
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has the opportunity to provide useful data that may not be contained in the basic,
formalized EHR.
Disadvantages of Data Mining
One major drawback to data mining is that clinicians are not typically charting
everything that occurs or is witnessed in a visit. Other times, some clinicians only chart
by exception, meaning that only when the patient presents findings outside the normative
expectations are they noted. There are times when data is missing or contrary to other
data within the EHR (Zozus et al., 2015).
Setting and Sample
Data was provided pertaining to patients receiving treatment at a multi-state,
multi-site, office-based outpatient addiction treatment center that primarily provides
medication treatment to patients with opioid use disorder. Patients meeting criteria for an
opioid abuse disorder according to the Diagnostic and Statistical Manual of Mental
Disorders (Fifth edition) (APA, 2013) are permitted to receive treatment at the center.
Upon admission, each patient undergoes a biopsychosocial assessment. Following this
assessment, an individualized treatment plan for each patient is developed. All sites
within the treatment organization have access to and utilize an electronic health record
(EHR) that provides robust monitoring. This allows all physicians and nurse
practitioners the ability to provide individualized care planning and management.
Opioid use disorders are primarily treated with buprenorphine in an outpatient
setting. The treatment center employs evidence-based treatment for a range of substance
use disorders (SUD), however most patient receive treatment for an opioid use disorder
(OUD). Given the focus of the study, only patients who received treatment for OUD will
be included in analyses. As numerous changes have occurred at the protocol level within
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the EHR, patients who received treatment between January 2016 and February 2018 will
be included to provide the most consistent treatment protocol. Prior to analyses, patients
under the age of 18 will be removed from the data file. This accounts for approximately
1% of the patients treated at the treatment centers.
Thus, in summary, inclusion criteria are patients who received treatment at an
outpatient treatment facility who received OUD care between January 2016 and February
2018 who received buprenorphine MT treatment. Exclusion criteria are patients who are
under the age of 18.
Sample Size
An important aspect of planning a research study is determining the sample size.
Ideally, the sample represents the population from which it is drawn so that findings can
then be generalized to the target population (Kadam & Bhalerao, 2010). The sample size
depends on several elements: the acceptable level of confidence, power of the study,
expected effect size, underlying rate of the condition under study in the population, and
standard deviation in a population (Kirby, Gebski, & Keech, 2002).
Power Analysis
Using G*Power 3.1.9.2, a power analysis was performed to estimate the required
sample size. In the analyses, the following parameters were used: power = 0.80, alpha =
0.05, and w = 0.1 (df=1). The effect size was based on a small effect size for contingency
table goodness of fit test. Based on these parameters, a sample size of 785 is required for
sufficient study power. The database provided included data for 19,970 patients, thus
there was ample power to complete this study.
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Operational Definition of Variables
The electronic health record (EHR) contains all the information that will be used
in this study. A description of all study variables is provided below.
Predictors
There are four main predictor variables in this study: Post traumatic stress
symptoms, a history of trauma, a history of involvement in the criminal justice system,
and gender. All four of the predictor variables are dichotomous and nominal.
Post-Traumatic Stress
During patient intake, patients provide an extensive medical and social history.
There are several locations in the EHR where data related to PTSD history could be
entered by a provider. Each of these fields is in free text format. Each of these fields is
in free text format. After translating all text data to lower case, syntax was written to
identify cases with a diagnosis of PTSD. The following phrases were identified in the text
fields and flagged as trauma positive: ptsd and post-traumatic stress. In addition, a patient
with any PTSD diagnosis code was identified as positive for PTSD.
Trauma
Similar to PTSD, during patient intake, patients provide an extensive medical and
social history. There are several locations in the EHR where data related to trauma
history could be entered by a provider. Each of these fields is in free text format. Text
from 500 was examined to identify provider specific phrases used to describe trauma in
the EMR. After translating all text data to lower case, syntax was written to identify cases
with evidence of a trauma history.
The following phrases were identified in the text fields and flagged as trauma
positive: stabbed, gunshot, traumatic, abused, hostage, victim of, rape, traumatic abuse,
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childhood abuse, hx abuse, intimate partner violence, domestic violence, gun shot, bullet
wound, trauma hx, physical abuse, sexual abuse, emotional abuse, assaulted, abuse as
child, stab wounds, beat up, being shot, verbal abuse, bullet lodged, shrapnel, stab injury,
sexually abused, physically abused, mugging, traumatic experiences, emotionally abuse,
domestic violence, past sexual trauma, violent incident, abusive relationship, stabbing
victim, molested, and kidnapped. In addition, a patient with a diagnosis code consistent
with trauma was identified as positive for trauma. In addition, any patient identified as
PTSD was also identified positive for trauma.
Involvement in the Criminal Justice System
The treatment provider evaluates patient involvement in the criminal justice
system i.e. probation, awaiting trial, and past incarceration each quarter when the
treatment plan is evaluated. This data is identified via check boxes. Providers are able to
check either that there are “pending criminal charges” or “resolved criminal charges.” If
a patient is positive for either, they were identified as involved with the criminal justice
system. In addition, several patients were identified as having involvement in the
criminal justice system through a separate database for patients who were part of a study
performed by the treatment center location. All patients in the “Jail Database” were
identified as positive for criminal justice system involvement.
Gender
Upon intake, during the patient’s history and physical exam, their gender is noted.
This was recorded as either male or female.
Dependent Variables
Several dependent variables will be examined in this study including visit
compliance, medication adherence, and drug use.
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Treatment Compliance
Patients that are more compliant with visits are considered to be progressing in
treatment by facility treatment providers (Hser et al., 2015b; Kampman & Jarvis, 2015;
Timko et al., 2016). There were several instances to assess visit compliance. There are
several types of encounters that are recorded in the EHR each time the patient is
scheduled for a visit. These types of visits where an encounter is created include:
provider visits, group visits, and random urine screen visits. Patients participate in group
therapy treatment focused on OUD antecedents and consequences. These sessions are
required as well as periodic random screening for opioid drug use. These encounters are
recorded as “no-show” when the patient does not appear for their session. Tracking the
number of times a patient does not come to a scheduled provider visit, a scheduled group
visit, a random urine screen visit, and cancels group visits provide the opportunity to
examine patient compliance.
In the current proposal, the following variables were examined: the number of “no
show visits”, number maintenance visits, number of initial visits, number of rejoin visits,
number of induction visits, number of group visits, number of no show group visits,
number of group cancellations, number of rescheduled visits, number of interruptions,
and number of other encounters. In addition, the total time in case and the time since the
last visit was evaluated.
Patients with more than one initial visit or more than one induction visit, are
having that visit because they had a period of stoppage in treatment. At the treatment
facility, a patient is defined as not in treatment if they have not been seen by a provider
within the past 30 days. The number of times a patient had more than 30 days outside of
treatment was summed and labeled the number of care interruptions.
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With the exception of the total time in care and the time since the last visit, all
variables were adjusted based on total time in care, by dividing the variable by how long
a patient had been in care.
Medication Adherence Since only patients treated with buprenorphine were
included in this study, medication adherence was defined as buprenorphine positive.
Urine screen data is available for every visit for each patient in the EHR. All
buprenorphine urine screens were used to create the variable percent positive for
buprenorphine. Positive screens were identified as “1”, while negative screens were
identified as “0.” All were summed and divided by the total number of buprenorphine
urine screens evaluated.
Drug Use
All drug use variables were obtained using the methodology described above. The
drugs examined included opioids, benzodiazepines, alcohol, THC, amphetamines,
cocaine, PCP, barbiturates, methamphetamines, and ecstasy. Percent positive for each of
the drug categories was constructed. A composite opioid values was constructed from the
following opioids: ultram, codeine, fentanyl, hydrocodone, hydromorphone, oxycodone,
hepridine, morphine, heroin, oxymorphone, propoxyphrene, and methadone. In addition,
there is a general opiate screen that was performed. At any visit a patient was identified
as positive is any of the opioids listed were positive. Since there was minimal usage of
PCP, barbiturates, methamphetamines, and ecstasy, these screens were summed as “other
drugs.”
Covariates
In addition to the variables already presented, other variables that were available
in the EHR were included in the analyses as covariates. These included age, race,
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ethnicity, and treatment center location. Since the sample is predominately white, a white
yes/no variable was constructed and used in analyses. Similarly, since the majority of the
patients were seen in Massachusetts, a Massachusetts yes/no variables was constructed
and used in analyses. Finally, total time in care and time since the last visit were included
as covariates when appropriate (i.e., when not the dependent variable).
Measurement of Variables
All variables were obtained from the EHR. The independent variables are nominal
in scale. Dependent variables are ratio in scale.
Procedures
The treatment center will provide all data in individual CSV data tables. All data
tables were imported into SPSS v25 and merged. Files were merged based on patient
MRN number. Prior to receiving the data, a study ID was created for each patient and a
de-identified data file was used for analyses. IRB approval from the University of
Massachusetts Amherst was received prior to data transfer.
Data Analysis
Prior to beginning study analyses, all variable distributions were evaluated for
normality or data entry errors. Descriptive statistics were calculated for all variables.
Analyses by study aim are described below.
Aim 1. To compare outcomes of Medication treatment (MT) success in patients
with elevated post-traumatic stress (PTS) and patients without PTS.
Analyses to examine Aim 1 were performed using ANCOVA. All covariates were
entered into the ANCOVA. An ANCOVA was performed for each of the dependent
variables. The independent variable PTSD was the between subjects variable. Gender

58

was also a between subjects variable and the interaction of PTSD and gender was
examined.
Aim 2: To compare outcomes of Medication treatment (MT) success in patients
with elevated history of trauma (Trauma+) and patients without a history of trauma.
Analyses to examine Aim 2 were performed using ANCOVA. All covariates were
entered into the ANCOVA. An ANCOVA was performed for each of the dependent
variables. The independent variable trauma was the between subjects variable. Gender
was also a between subjects variable and the interaction of trauma and gender was
examined.
Aim 3: To compare outcomes of Medication treatment (MT) success in patients
with an history of involvement with the criminal justice system (CJS) and patients without
a history of involvement in CJS.
Analyses to examine Aim 3 were performed using ANCOVA. All covariates were
entered into the ANCOVA. An ANCOVA was performed for each of the dependent
variables. The independent variable CJS involvement was the between subjects variable.
Gender was also a between subjects variable and the interaction of CJS involvement and
gender was examined.
Aim 4. To examine if PTS status moderates the relationship between involvement
in the criminal justice system and Medication Treatment success.
Analyses to examine Aim 4 were performed using ANCOVA. All covariates were
entered into the ANCOVA. An ANCOVA was performed for each of the dependent
variables. The independent variable PTS and CJS involvement were the between subjects
variables. Gender was also a between subjects variable and the interaction of PTSD and
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gender was examined. Evidence of moderation was evaluated using the PTSD * CJS
interaction term.
Aim 5. To examine if trauma status moderates the relationship between
involvement in the criminal justice system and Medication Treatment success.
Analyses to examine Aim 5 were performed using ANCOVA. All covariates were
entered into the ANCOVA. An ANCOVA was performed for each of the dependent
variables. The independent variable trauma status and CJS involvement were the between
subjects variables. Gender was also a between subjects variable and the interaction of
trauma and gender was examined. Evidence of moderation was evaluated using the
TRAUMA * CJS interaction term.
Limitations
Term Abstraction
Term abstraction is identified as a potential limit to the study. Term abstraction is
the process in which terms related to PTS+ were identified and programmed for
recognition by SPSS. The terms themselves may be limiting and may not encompass all
terms used by a provider or patient to identify a particular functional outcome. There is
also the potential that some terms referring to functional outcomes may be used in the
note written by the provider but not recognized due to their novelty.
Protection of Human Subjects
While the use of patient data should always be treated with the highest regard for
confidentiality, using de-identified data within a secondary analysis will lessen the
opportunity for breach of anonymity. This study will follow criteria set forth by the
University of Massachusetts Amherst Institutional Review Board and received board for
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approval. All investigators completed the requisite training regarding the protection of
human subjects to ensure that no harm comes to patients involved in this study.
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CHAPTER 4
RESULTS
This chapter describes the results of the study. It contains pertinent descriptive
data used to identify the general characteristics of the study sample and covariates
including: age, gender, ethnicity, state of treatment, race. The chapter also outlines the
various levels of positive drugs screens throughout the sample. This chapter also
provides results based on the predictor variables (PTSD and History of Incarceration) and
dependent variables (provider visit compliance, group visit compliance, random visit
compliance, medication adherence, and illicit opioid use) utilized within various
regression and mediation analyses as outline in the chapter 3.
Sample
The study sample consisted of 19,848 subjects ranging in age from 18-83 years
with a mean age of 38.3 years (SD= 10.6). The majority of the sample was male at 57.8%
and 69.9% white and received treatment within the state of Massachusetts (69.9%). Just
under 10% (9.5%) of the sample have a history of PTSD; while just over 10% a history of
Trauma was noted in 12.0% of the sample. A total of 5115 (22.8%) subjects had an
involvement in the criminal justice system (see Table 2).
Table 2. Sample Characteristics (N=19,970).
Socio-demographic Variables
Sex
Male
Race
White
Non-white
Ethnicity
Hispanic
Non-Hispanic
State of Treatment
Massachusetts

%
57.3
67.8
32.2
12.7
87.3
69.9
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All other states
PTSD (% yes)
Trauma (% yes)
Criminal Justice Involvement (% yes)

30.1
9.5
12.0
22.8

Relationship between Trauma, PTSD, CJS and Demographic Characteristics
The relationship between PTSD, trauma history, and criminal justice status (CJS)
was evaluated via chi-square (see Table 3). Due to high study statistical power, a
conservative alpha was used to evaluate statistical significance (α = 0.05). Gender was
significantly related to PTSD, trauma, and CJS involvement. More women were
identified as having a history of PTSD (χ2 =211.0, p < 0.001) and trauma (χ2 = 234.7, p <
0.001), while more men had a history of CJS (χ2 = 14.0, p < 0.001). Ethnicity was not
significantly related to PTSD status (χ2 = 0.009, p = 0.925) or CJS involvement (χ2 = 0.4,
p = 0.542), but was significantly related to trauma status (χ2 = 18.5, p < 0.001). Hispanic
patients had reported less trauma history that non-Hispanic patients. No significant
relationships were found between race and PTSD (χ2 = 3.7, p < 0.054) or trauma (χ2 =
2.1, p = .145). White patients did report a significantly higher CJS (χ2 = 17.1, p < 0.001).
As mentioned above, the majority of the patients were treated in Massachusetts (69.9%).
Given the small number of patients treated in any of the other individual states, a
dichotomous Massachusetts variable (treated in MA yes/no) was created and used in
analyses. The state in which the subjects were treated showed significant proportions.
Massachusetts has the largest proportion of subjects with PTSD at 11.6% (p < 0.001),
trauma at 13.2% (p = 0.009) and CJS at 24.9 % (p < 0.001).
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Table 3. PTSD/Trauma/CJS status and demographic characteristics.
PTSD Status
Variables
Sex

No

Yes

(n=17,876) (n=1,945)

%

%

Male

92.8

7.2

Female

86.6

13.4

White

89.8

10.3

Non-White

95.7

4.3

Hispanic

89.9

12.6

Non-Hispanic

89.8

87.4

88.4

11.6

94.0

6.0

Trauma Status
χ2

211.0***

No

Yes

(n= 17,278) (n=2,543)

%

%

90.3

9.7

83.0

17.0

86.9

13.1

88.7

11.3

90.3

9.7

86.8

13.2

86.8

13.2

88.1

11.9

CJS Status
χ2

No
%

234.7***

Yes

χ2

(n=15,303) (n=4,664)

%

75.6

24.4

77.9

22.1

76.4

23.6

82.8

17.2

14.0***

Race
3.7

2.1

17.1***

Ethnicity
0.0

18.5***

76.9

23.1

76.3

23.7

0.4

State
Massachusetts
Other

150.4***

6.8**

75.1

24.9

79.9

20.1

57.6***

**p<.01. ***p<.001
Relationship between Trauma, PTSD, CJS and Treatment Compliance
The relationships between treatment visit compliance among PTSD, trauma
history, and criminal justice status (CJS) was evaluated via independent sample t-tests
(see Table 4) to evaluate for statistical significance. All relationships were significant for
all three IV variables evaluated: PTSD (yes/no), Trauma history (yes/no), and CJS
(yes/no). Individuals who were positive for PTSD, trauma, or CJS had significantly more
“no show” visits than without a trauma history (t’s = -12.6, -19.7, -30.7, all p’s < 0.001
respectively). Similarly, all risk groups for the three variables examined had more group
cancellations (t’s = (-2.7, p = 0.007), (-5.5, p < 0.001), (-6.7, p < 0.0010 respectively),
group “no show” visits (t’s = -7.4, -15.9, -21.0, all p’s < 0.001 respectively), and
reschedules visits (t’s = -11.4, -19.6, -26.5, all p’s < 0.001 respectively). All of these
relationships suggest problems with treatment compliance which is supported by
significantly more care interruptions for those with PTSD (t = -8.0, p < 0.001), trauma (t
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= -5.8, p < 0.001) and positive CJS status (t = -17.7, p < 0.001). However, each of the
risk groups for PTSD, Trauma, and CJS have significantly more maintenance visits (t’s =
-13.1, -29.8, -37.2, all p’s < 0.001 respectively) and group visits (t’s = -8.4, -22.2, -26.7,
all p’s < 0.001 respectively). At risk groups had been in care longer (t’s = -10.1, -25.2, 31.5, all p’s < 0.001 respectively) and had been seen more recently (t’s = 5.1, 23.5, 12.8,
all p’s < 0.001 respectively). These data suggest increased compliance. However, more
initial visits (t’s = -16.7, -11.3, -22.1, all p’s < 0.001 respectively), more rejoin visits (t’s
= -11.8, -13.5, -25.3, all p’s < 0.001 respectively), and more induction visits (t’s = -10.1, 15.1, -25.5, all p’s < 0.001 respectively) for all three risk groups support care
interruptions and lower treatment compliance. Overall, the data suggest poorer treatment
compliance for all three risk groups.
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Table 4. Relationships between PTSD, Trauma, CJS, and Treatment Compliance.
PTSD Status
Treatment
Compliance

Trauma Status

Total

No

Yes

Mean

Mean

Mean

t

No

Yes

Mean

Mean

CJS Status

t

No

Yes

Mean

Mean

t

# no show visits

3.3

3.2

4.8

-12.6***

3.0

5.6

-19.7***

2.6

5.5

-30.7***

Time since last visit
(yrs.)

0.6

0.6

0.5

5.1***

0.6

0.3

23.5***

0.6

0.5

12.8***

# maintenance visits

28.1

27.0

40.5

-13.1***

24.5

54.1

-29.8***

21.9

48.5

-37.2***

# initial visits

0.8

0.8

0.9

-16.7***

0.8

0.9

-11.3***

0.8

0.9

-22.1***

# rejoin visits

0.4

0.3

0.6

-11.8***

0.3

0.6

-13.5***

0.3

0.7

-25.3***

# induction visits

0.7

0.7

0.9

-10.1***

0.7

0.9

-15.1***

0.6

0.9

-25.5***

# group visits

1.3

1.2

1.7

-8.4***

1.1

2.3

-22.2***

1.0

2.0

-26.7***

# no show group
visits

0.5

0.5

0.7

-7.4***

0.4

0.9

-15.9***

0.4

0.9

-21.0***

# group cancellations

0.0

0.0

0.0

-2.7**

0.0

0.0

-5.5***

0.0

0.0

-6.7***

# rescheduled visits

3.2

3.1

5.0

-11.4***

2.8

6.0

-19.6***

2.5

5.6

-26.5***

Total time in care

1.1

1.1

1.4

-10.1***

1.0

1.9

-25.2***

0.9

1.7

-31.5***

# of interruptions

0.8

0.8

1.0

-8.0***

0.8

1.0

-5.8***

0.7

1.1

-17.7***

# other encounters

25.6

24.4

37.7

-16.7***

22.7

46.4

-31.2***

19.9

41.3

-51.0***

**p<.01. ***p<.001

Relationship between PTS, Trauma, & CJS and MT Adherence & Drug Use
Medication Adherence
The relationship between PTSD, trauma, and CJS and medication adherence was
evaluated using independent t-tests (Table 5). Mean percent positive buprenorphine
screens were significantly higher for individuals positive for PTSD, trauma, or CJS (t’s =
-6.4, -21.9, -21.8, all p’s < 0.001 respectively). These data show increased compliance for
medication for all three at risk groups. These data do not support the hypothesis that
individuals with trauma history, PTSD, or CJS are less compliant with MT.
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Drug Use
The relationship between PTSD, trauma, and CJS and drug use was evaluated
using independent t-tests. Those positive for PTSD, trauma, and CJS had significantly
lower mean percent positive for opioid screens (t’s = 6.7, 16.5, 17.1, all p’s < 0.001)
suggesting better outcomes for all three risk groups. However, all three risk groups had
more positive amphetamine screens (t’s (-4.7, p < 0.001), (-6.9, p < 0.001), (-3.0, p =
0.003 respectively). Individuals with PTSD had more cocaine screens (t = -4.0, p < .001)
and alcohol use (t = 2.4, p < .016). None of the three risk groups had significantly more
other drug use. There was less methadone use in patients with trauma and in patients
positive for CJS. Finally, patients with PTSD and trauma had significantly more
benzodiazepine screens (t’s = -11.2 and -6.3, both p’s < 0.001 respectively).
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Table 5. Relationship between medication adherence and drug use by PTSD/Trauma/CJS
Total
Sample
Drug (%
positive)

PTSD
Status
No

Yes

Trauma
Status
t

CJS
Status

No

Yes

t

No

Yes

t

80.5 89.1
17.1 12.1

21.8***
17.1***

5.6 6.4

-3.0**

Buprenorphine

76.5

82.4

86.2 -6.4***

81.4

90.9

Opiates †

15.3

16.0

13.2

6.7***

16.5

11.0

21.9***
16.5***

5.5

5.6

7.6 -4.7***

5.4

8.0

-6.9***

Cocaine

16.1

16.2

19.1 -4.0***

16.7

15.7

1.8

16.3 17.2

-1.9

THC

33.1

33.3

37.3 -4.1***

33.7

34.3

-0.8

33.9 33.7

-0.2

Alcohol

15.0

14.7

13.3

2.4

14.6

14.3

0.7

14.7 14.1

1.5

Other ††

7.2

7.3

8.0 -0.6

7.1

8.6

-1.8

7.1 8.0

-1.2

Methadone

2.2

2.2

2.0

2.3

1.6

3.9***

2.5 1.3

Benzodiazepines

9.3

8.7

13.8

9.0

11.2

-6.3***

9.3 9.3

Amphetamines

1.1
11.2***

9.0***
-0.3

**p<.01. ***p<.001
†
– Ultram, codeine, fentanyl, hydrocodone, hydromorphone, oxycodone, hepridine,
morphine, heroin, oxymorphone, propoxyphrene.
††
– PCP, barbiturates, methamphetamines, ecstasy.
Summary
In summary, patients who received treatment in Massachusetts, were white, nonHispanic. Almost 25% of the sample had some involvement in the criminal justice
system, 9.5% had PTSD, and 12% had a history of trauma. Patients in each risk groups
showed poorer treatment compliance with more “no show” provider and group visits and
a higher number of overall encounters. These risk groups also had a higher frequency of
attendance to maintenance visits. Patients with PTSD, trauma, and CJS had better
medication adherence, but mixed results in drug screen results.
Analysis of Study Aims
AIM 1 –To compare outcomes of Medication treatment (MT) success in patients
with elevated post-traumatic stress (PTS) and patients without PTS.
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To examine the relationship between PTSD, Trauma, and CJS, several
ANCOVAs were performed. The between-subjects variable for all analyses were either
PTSD history (yes/no), trauma history (yes/no), CJS involvement (yes/no) and gender
(male/female). Dependent variables included measures of treatment compliance,
medication adherence, and drug use. In addition to main effects, gender by PTSD,
Trauma, or CJS interaction terms were evaluated. The covariates in the analyses included
race, treatment state, age, ethnicity, total time in care, and time since last visit. For study
aim analyses, a more conservative level of statistical significance was used (α = 0.01) due
to high statistical power and the number of comparisons being evaluated.
Relationship between PTSD and Treatment Compliance
After including covariates, there were many significant differences in treatment
compliance by PTSD history. Individuals with a history of PTSD had more “no shows”
for maintenance visits (F(9, 12853) = 83.0, p<.001) than individuals without a history of
PTSD, but there was no difference in frequency of “no shows” for group visits (F(9,
12853) = 2.2, p= 0.155). Individuals with PTSD had more initial visits, rejoin visits,
inductions, and care interruptions (F(9, 12853) = 83.0, p<.001), (F(9, 12853) = 61.4,
p<.001), (F(9, 12853) = 45.2, p<.001), (F(9, 12853) = 19.4, p<.001 respectively) than
individuals without a history of PTSD. When an individual lapses from the program, as
evidenced by increased care interruptions, and “rejoins” the program, they will have
another initial visit and induction visit. Thus, there is evidence that individuals with
PTSD have more care interruptions than individuals without a history of PTSD
suggesting poorer treatment outcomes (see Table 6).
Supporting data includes individuals with PTSD also had more total encounters
(F(9, 12853) = 140.0, p<.001). After controlling for the amount of time in care and the

69

time since the last visit, staff interacted with patients with a history of PTSD more than
individuals without a history of PTSD. Although individuals with a history of PTSD
rescheduled their maintenance visit more frequently (F(9, 12853) = 24.0, p<.001), they
also had more overall maintenance visits (F(9, 12853) = 36.0, p<.001). Finally, there was
also a significant relationship between PTSD status and total time in care (F(8, 12854) =
20.3, p<.001) and the time since the last visit (F(7, 13369) = 23.5, p<.001). Patients with
a history of PTSD were in care longer and had a shorter length of time since they were
last seen.
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Table 6. Relationship between Treatment Compliance and PTSD, Gender, and
PTSD*Gender.
Treatment Compliance

PTSD

Gender

PTSD X
Gender

F

F

F
# no show visits

45.1***

# initial visits

83.0***

5.0

2.2

# rejoin visits

61.4***

0.4

0.8

# induction visits

45.2***

1.9

0.1

# care interruptions

19.4***

1.6

2.8

3.2

0.3

# group cancellations

0.2

# rescheduled visits

24.0***

# maintenance visits

36.0***

# other encounters

11.6***

139.9***

32.4***
0.5
35.6***

0.4

0.1
0.1
0.5

# group visits

0.3

0.4

0.5

# no show group visits

2.0

0.7

3.2

4.7

0.0

Time since last visits (yrs) †

23.5***

Total time in care (yrs) ††
20.3***
28.1***
†
Time since last visit was not included as a covariate.
††
Total time in care was not included as a covariate.
**p<0.01. ***p<0.001.

2.6

Relationship between Gender and Treatment Compliance
After including covariates, there were many significant differences in treatment
compliance by Gender (see Table 7). Women had more “no show” maintenance visits
(F(9, 12853) = 11.6 p = .001) and rescheduled their visits more frequently (F(9, 12853) =
24.0, p<.001) than men. Women also had a statistically significant greater number of
encounters (F(9, 12853) = 35.6, p <.001). Women were also in care longer (F(9, 12854)
= 28.1, p< .001). There were no significant PTSD by gender interactions.
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Relationship between Covariates and Treatment Compliance
There were significant relationships between all covariates and at least some
measures of treatment compliance (Table 8). The race of the patient was related to
induction visits (F(9, 12853) = 8.4, p = .004) and total time in care (F(9, 12853) = 16.5, p
< .001). White patients had less induction visits than non-white patients. Patients in
Massachusetts had poorer compliance on the majority of the variables examined. For
example, patients treated in Massachusetts were more likely to not attend scheduled
maintenance visits (F(9, 12853) = 191.2, p < .001), and had more initial (F(9, 12853) =
48.4, p < .001), rejoin (F(9, 12853) = 158.5, p < .001), and induction visits (F(9, 12853)
= 95.8, p < .001). However, Massachusetts patients had more total time in care (F(9,
12853) = 1880.2, p < .001).
Age was significantly related to treatment compliance measures. As patient’s age
increased, the rate of “no show” visits (F(9, 12853) = 226.2, p < .001), rejoin visits (F(9,
12853) = 42.8, p < .001), rescheduled visits (F(9, 12853) = 89.1, p < .001) and care
interruptions (F(9, 12853) = 70.0, p < .001) decreased. For patients, as age increased,
groups visits (F(9, 12853) = 56.8, p < .001), encounters (F(9, 12853) = 129.6, p < .001),
and total time in care (F(9, 12853) = 153.4, p < .001) increased. In regard to ethnicity,
Hispanic patients were more likely to have more induction visits (F(9, 12853) = 16.2, p <
.001) and attend maintenance visits (F(9, 12853) = 8.7, p = .003). Non-Hispanic patients
were more likely to attend group visits (F(9, 12853) = 26.7, p < .001). Total time in care
was significantly related to all treatment compliance measures. As the total time in care
increased, so did the number of “no show” visits (F(9, 12853) = 1873.0, p < .001),
maintenance visits (F(9, 12853) = 42048.3 p < .001), rejoin visits (F(9, 12853) =
663.422, p < .001), induction visits (F(9, 12853) = 16.5, p < .001), groups visits (F(9,
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12853) = 11563.8, p < .001), group “no show” visits (F(9, 12853) = 3429.0, p < .001),
group cancelations (F(9, 12853) = 487.9, p < .001), encounters (F(9, 12853) = 11920.2, p
< .001, and time since last seen. In contrast, as total time in care increased, the number of
initial visits (F(9, 12853) = 186.0, p < .001) and rescheduled visits (F(9, 12853) =
3625.6, p < .001) decreased. As the time since last seen increased, total time in care (F(9,
12854) = 1410.9, p < .001), attendance at maintenance visits (F(9, 11566) = 47.8, p <
.001), and group visits (F(9, 12853) = 574.6, p < .001) decreased.
Table 7. Relationship between Covariates and Treatment Compliance.
Treatment Compliance

Race

Location

F

F

Age
F

Ethnicity
F

Care Time

Last Seen

F

F

# no show visits

5.7

191.2***

226.3***

5.6

1873.0***

6.5

# initial visits

0.4

48.4***

0.4

2.9

186.0***

397.8***

# rejoin visits

2.6

158.5***

42.8***

3.9

663.4***

2.9

# induction visits

8.4**

95.8***

7.3**

16.5***

59.7***

# care interruptions

0.0

172.5***

70.0***

4.1

329.0***

91.8***

# group cancellations

0.1

1.1

0.2

487.9***

5.1

# rescheduled visits

1.8

116.4***

0.2

3625.6***

24.3***

# maintenance visits

0.8

28.0***

0.1

8.7**

42048.3**

270.4***

# other encounters

5.6

22.9***

129.7***

5.6

*
11920.2**

99.9***

# group visits

3.8

37.4***

56.8***

*
11563.8**

574.6***

# no show group visits

0.1

29.8***

66.8***

*
3429.0***

69.3***

Time since last visits (yrs)

5.8

689.9***

3.7

2.5

NA

36.2*

1880.2**

153.4***

3.6

NA

Total time in care (yrs)
**p<.01. ***p<.001

**

0.1

*

89.1***

16.2***

26.7***
4.3

NA
1411.0**
*
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MT Adherence and Drug Use within PTSD
Medication Adherence
The relationship between PTSD, medication adherence, and drug use was
evaluated using ANCOVA (Table 9). The PTSD group demonstrated greater medication
adherence than the non-PTSD group. Consistent with the bivariate analyses, after
controlling for covariates, patients with PTSD had a significantly greater number of
positive buprenorphine screens than patients without PTSD (F(9, 11599) = 17.7, p <
.001).
Drug Use
Although more compliant with buprenorphine, patients with PTSD had
significantly more benzodiazepine use (F(9, 11599) = 76.5, p < .001), THC use (F(9,
11599) = 12.8, p < .001), amphetamine use (F(9, 11599) = 10.7, p = .001), cocaine use
(F(9, 11599) = 18.0, p < .001), and opioid use (F(9, 11599) = 17.8, p < .001). PTSD
status was unrelated to alcohol, methadone, and other drug use.
Gender
Men with PTSD used alcohol more frequently than women with PTSD (F(9,
11599) = 21.4, p < .001) as well as THC (F(9, 11566) = 35.6, p < .001). In contrast,
women were more positive for benzodiazepines than men (F(9, 11599) = 19.7, p < .001).
There were no significant PTSD by gender interactions.
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Table 8. Relationship between Medication adherence/Drug Use and PTSD/Gender.
Drugs (% positive)

PTSD

Gender

PTSD X
Gender

F

F

F

Buprenorphine

17.7***

0.4

0.2

Benzodiazepine

76.5***

19.7**

0.0

THC

12.8***

*
35.6**

1.1

Amphetamine

10.7**

*3.8

2.7

4.0

21.4**

0.2

Alcohol
Cocaine

18.0***

*
0.0

0.2

Opioids All

17.8***

0.1

0.1

Methadone

0.4

0.2

0.1

Other drug

2.8

1.1

1.4

**p<.01. ***p<.001

Relationship between Covariates and MT Adherence and Drug Use
Medication Adherence
There were significant relationships between co-variates and measures of
medication adherence and drug use (Table 10). Compliance with buprenorphine was
predicted by race (F(9, 11599) = 44.1, p < .001) and treatment location (F(9, 11599) =
30.2, p < .001). White patient buprenorphine screens were more positive than non-white
patients, while screens for patients treated in Massachusetts were less often positive,
suggesting less medication adherence. Non-Hispanic patients (F(9, 11599) = 7.6, p <
.006), were more compliant with their buprenorphine than Hispanic patients. The
patients that spent more total time in care (F(9, 11599) = 861.5, p < .001) had more
positive buprenorphine screens. As patients’ time since last seen (F(9, 11566) = 296.4, p
< .001) increased, their percentage of buprenorphine decreased.
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Drug Use
Patients in Massachusetts used alcohol (F(9, 11566) = 47.8, p < .001), THC (F(9,
11599) = 64.7, p < .001), cocaine (F(9, 11566) = 123.1, p < .001), and opioids (F(9,
11566) = 30.1, p < .001) more frequently than patients in other states. Patient race was
not related to benzodiazepines, alcohol, methadone, and other drugs, but White patients
were less likely to use THC (F(9, 11566) = 12.4, p < .001), cocaine (F(9, 11567) = 50.2,
p < .001), and opioids (F(9, 11599) = 40.3, p < .001). In contrast, White patients used
amphetamines (F(9, 11566) = 20.0, p < .001) more frequently. Although Hispanic
patients were less likely to use benzodiazepines (F(9, 11567) = 21.0, p < .001), alcohol
(F(9, 12853) = 8.2, p = .004) and amphetamines (F(9, 11566) = 27.4, p < .001), Hispanic
patients were more likely to use THC (F(9, 11566) = 5.2, p = .022), cocaine (F(9, 11567)
= 13.1, p = .001) and opioids (F(9, 11599) = 16.2, p < .001).
Age was significantly related to all medication adherence and drug use. As
patient’s age increased, the percent positive for screens of alcohol (F(9, 11562) = 52.6, p
< .001) benzodiazepines (F(9, 11567) = 106.6, p < .001), and methadone (F(9, 11582) =
18.5, p < .001) increased. As the age of the patient increased, the percent positive screen
of opioids (F(9, 11599) = 41.5, p < .001) decreased. Total time in care was related
significantly to medication adherence (F(9, 11599) = 861.5, p < .001) with an increase in
buprenorphine use. As patients spent more time in care, the positive percent of
buprenorphine increased. As the total time in care increased, alcohol (F(9, 11567) =
16.8, p < .001), cocaine (F(9, 11567) = 374.5, p < .001), methadone (F(9, 11582) = 84.1,
p < .001), opioids (F(9, 11567) = 1065.2, p < .001), other drugs (F(9, 2441) = 4.1, p <
.027) all decreased in positive screens. As total time in care increased, amphetamines
(F(9, 11566) = 11.7, p = .001) and THC (F(9, 11566) =4.5, p < .034) increased in
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positive screens. Time since last seen was significantly related to all medication
adherence and some drug measures. As the time since last seen increased, positive
buprenorphine (F(9, 11599) = 296.4, p < .001) screens decreased. As time since last seen
increased, the use of benzodiazepines (F(9, 11567) = 64.3, p < .001), alcohol (F(9,
11562) = 9.126, p < .003), methadone (F(9, 11582) = 19.5 p < .001), and opioids (F(9,
11599) = 407.9, p < .001) all increased.
Table 9. Relationship between Medication adherence/Drug Use results and covariates
Drugs (%
positive)

Race
F

Buprenorphine

44.1***

Benzodiazepine

4.8

Alcohol

0.3

Location
F

Age

Ethnicity

Care Time

F

F

3.4

7.6**

861.5***

296.4***

106.6***

20.9***

0.2

64.3***

47.8***

52.6***

8.2**

30.2***
0.5

F

Last Seen

16.8***

F

9.1**

THC

12.3***

64.7***

367.0***

5.2*

4.5

0.0

Amphetamine

20.0***

56.2***

3.3

27.4***

11.7**

3.3

Cocaine

50.2***

123.1***

3.5

13.1***

374.5***

1.4

Methadone

0.5

0.6

Other drug

2.3

740.4***

Opioids All

40.3***

30.1***

18.5***
0.6
41.5***

3.6
0.1
16.2***

84.1***
4.9
1065.2***

19.5***
0.5
408.0***

**p<.01. ***p<.001

Summary of PTSD Results
Patients with a history of PTSD spent more time in care and attended more
individual and group visits. These patients had difficulty attending their scheduled
meetings, had more initial visits as well as induction visits, and had a larger total number
of other encounters. While these patients utilized opioids, benzodiazepines, and THC
more than those without PTSD, they were also more compliant with their medication
adherence in the form of buprenorphine.
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AIM 2 – To compare outcomes of Medication treatment (MT) success in patients
with elevated and patients without PTS.
Relationship between Trauma and Treatment Compliance
After including covariates, there were many significant differences in treatment
compliance by trauma history. Individuals with a history of trauma had more “no shows”
for maintenance visits (F(9, 12853) = 116.6, p < .001) than individuals without a history
of trauma, but there was no difference in frequency of “no shows” in group visits (F(9,
12853) = 2.0, p= 0.157). Individuals with trauma had more initial visits (F(9, 12853) =
33.7, p < .001), rejoin visits (F(9, 12853) = 57.6, p < .001), inductions (F(9, 12853) =
106.1, p < .001), and care interruptions (F(9, 12853) = 8.3, p = .004) than individuals
without a history of trauma. Those with a history of trauma also rescheduled their
maintenance visits more frequently (F(9, 12853) = 47.5, p < .001). There is evidence that
individuals with trauma had poorer treatment compliance outcomes than individuals
without a history of trauma (see Table 11).
Analyses not consistent with poorer treatment compliance include individuals
with a history of trauma had more maintenance visits (F(9, 12853) = 132.0, p < .001)
more other encounters (F(9, 12853) = 265.3, p = .000), total time in care (F(9, 12853) =
420.8, p < .001), and had been seen more recently (F(9, 12853) = 274.7, p<.001).
Gender and Treatment Compliance
After including covariates, there were significant differences in treatment
compliance by gender. Women had more “no show” visits for individual maintenance
visits (F(9, 12853) = 50.2, p < .001) and group visits (F(9, 12853) = 9.3, p = .002) than
men. In addition, women rescheduled more than men (F(9, 12853) = 91.0, p < .001) had
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more total overall encounters (F(9, 12853) = 117.1, p<.001) and were in care longer than
men (F(9, 12854) = 24.2, p< .001).
Table 10. Relationship between Trauma, Gender, and Treatment Compliance.
Treatment Compliance

# no show visits

Trauma

Trauma X
Gender

Gender

F

F

116.6***

50.2***

F
31.4***

# initial visits

33.7***

2.7

1.0

# rejoin visits

57.6***

1.3

0.2

106.1***

2.3

0.0

# care interruptions

8.3**

3.9

1.1

# group cancellations

0.6

4.5

0.7

# induction visits

# rescheduled visits

47.5***

# maintenance visits

132.0***

0.4

# other encounters

265.3***

117.1***

# group visits

0.1

1.9

3.5

# no show group visits

2.0

9.3**

0.5

2.8

0.1

Time since last visits (yrs)

274.7***

Total time in care (yrs)

420.8***

91.1***

24.3***

17.2***
0.4
46.8***

4.1

**p<.01. ***p<.001

When examining the impact gender on the relationship between trauma and
treatment compliance, three significant interactions were identified (see Table X). There
was a significant interaction between trauma and gender and the number of “no show”
visits (F(9, 12853) = 31.4, p < .001). For individuals without trauma, there was not a
difference in “no show” visits by gender. In contrast, among those with PTSD, women
had a higher number of “no show” visits then men (see Figure 3).
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5.50

Number of No Shows

5.00
4.50
4.00
3.50
3.00
No Trauma

Trauma
Men

Women

Figure 3. Trauma X Gender Interaction within “No Show” Visits.
There was also a significant interaction between trauma and gender on the number
of rescheduled visits (F(9, 12853) = 17.2, p < .001). Similar to the number of “no show”
visits, men had a comparable number of rescheduled visits regardless of PTSD status.
Women with PTSD had more rescheduled visits than women without PTSD (see Figure
4).

Number of Reschedules

5.50
5.00
4.50
4.00
3.50
3.00
No Trauma

Men

Women

Figure 4. Trauma X Gender Interaction within Rescheduled Visits.
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Trauma

Finally, there was a significant interaction between trauma and gender and the
number of total number of encounters (F(9, 12853) = 46.8, p < .001). Men and women
without a history of trauma had a similar number of encounters. For those with a trauma
history, women had more overall encounters than men (see Figure 5).
40.00

Number of Encounters

38.00
36.00
34.00
32.00
30.00
28.00
26.00
24.00
No Trauma

Men

Women

Trauma

Figure 5. Trauma X Gender Interaction and Number of Encounters.
Relationship between Covariates and Treatment Compliance
There were significant relationships between covariates and several measures of
treatment compliance (Table 12). All relationships between compliance measures and
treatment state were significant with the exception of group cancellations visits. Patients
in Massachusetts had poorer compliance on the majority of the variables examined. For
example, patients treated in Massachusetts were more likely to not attend scheduled
maintenance visits (F(9, 12853) = 222.7, p < .001), and had more rejoin visits (F(9,
12853) = 181.1, p < .001), and induction visits (F(9, 12853) = 113.8, p < .001).
However, Massachusetts patients had more total time in care (F(9, 12853) = 1936.0, p <
.001) and more encounters (F(9, 12853) = 41.5, p < .001). Patient race was unrelated to
all covariates except induction visits (F(9, 12853) = 8.5, p = .004) and total time in care
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(F(9, 12853) = 34.6, p < .001). Non-whites were more likely to have more induction
visits and less total time in care. Hispanic patients were significantly less likely to have
“no show” maintenance visits (F(9, 12853) = 6.8, p = .009), attended more group visits
(F(9, 12853) = 26.7, p < .001), and had more induction visits (F(9, 12853) = 18.6, p <
.001). Hispanic patients also had a significantly higher rate of maintenance visits (F(9,
12853) = 10.3, p = .001).
Age was significantly related to compliance measures such as attending “no
shows” to maintenance visits (F(9, 12853) = 231.5, p < .001), rejoin visits F(9, 12854) =
43.561, p < .001), encounters F(9, 12853) = 135.0, p < .001), and total time in care F(9,
12853) = 142.7, p < .001). With the exception of induction visits, total time in care was
significantly related to all treatment compliance measures. As the total time in care
increased, the number of no shows (F(9, 12853) = 1674.6, p < .001), maintenance visits
(F(9, 12853) = 40303.6 p < .001), rejoin visits (F(9, 12853) = 590.4, p < .001), induction
visits (F(9, 12853) = 49.9, p < .001), groups visits (F(9, 12853) = 11208.0, p < .001),
group no shows (F(9, 12853) = 3292.1, p < .001), group cancels (F(9, 12853) = 466.8, p
< .001), encounters (F(9, 12853) = 11144.5, p < .001, and time since last seen (F(9,
12853) = 1227.5, p < .001 all increased. The number of initial visits (F(9, 12853) =
197.9, p < .001) and rescheduled visits (F(9, 12853) = 3384.2, p < .001), decreased with
the more time spent in care. As the time since patients were last seen increased the total
time in care (F(9, 12854) = 1227.5, p < .001), maintenance visits F(9, 12853) = 246.0, p
< .001) and group visits F(9, 12853) = 570.2, p < .001) all decreased.
Table 11. Relationship between Treatment Compliance and Covariates.
Treatment Compliance

Race

Location

Age

F

F

F
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Ethnicity
F

Care Time

Last Seen

F

F

# no show visits

5.8

222.7***

231.5***

# initial visits

0.4

60.6***

0.4

# rejoin visits

2.5

181.8***

43.6***

# induction visits

8.5**

113.8***

7.8**

# care interruptions

0.0

186.2***

70.4***

# group cancellations

0.1

1.3

# rescheduled visits

1.9

132.7***

# maintenance visits

0.8

38.1***

# other encounters

5.7

# group visits

6.8**

1674.3***

3.3

3.7

197.9***

385.0***

4.9

590.4***

4.5

5.8

49.9***

4.6

306.2***

93.6***

0.2

466.8***

0.1

3384.2***

20.0***

0.0

10.3**

40303.6***

246.0***

41.5***

135.0***

4.0

11144.5***

80.8***

3.8

36.9***

56.6***

11208.0***

570.2***

# no show group visits

0.1

31.4***

66.7***

4.1

3292.1***

67.5***

Time since last visit (yrs)

6.6

694.1***

2.1

3.6

NA

NA

1936.0***

142.7***

2.4

NA

1227.5***

Total time in care (yrs)

34.6***

0.2
90.5***

18.4***

26.7***

5.3

**p<.01. ***p<.001

Relationship between Trauma, MT Adherence, and Drug Use
Trauma, medication adherence, and drug use were evaluated using ANCOVA
(table 13). The trauma group demonstrated greater medication adherence than the nontrauma group. Consistent with the bivariate analyses, after controlling for covariates,
patients with a history of trauma had a significantly greater number of buprenorphine
positive screens than patients without a history of trauma (F(9, 12853) = 24.3, p <.001).
Drug Use
Although more compliant with their medication, those with a trauma history
demonstrated significantly increased use of benzodiazepines (F(9, 12853) = 21.3, p <
.001), amphetamines (F(9, 12853) = 18.1, p < .001) and cocaine (F(9, 12853) = 18.5, p <
.001). Unlike the PTSD group, the trauma and non-trauma group did not demonstrate a
significant difference in their use of opioids (F(9, 12853) = 2.0, p = .165).
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Gender
Men had higher rates of drug use for the majority of the drugs tested. Men used
more alcohol (F(9, 12853) = 18.096, p < .001), other drugs (F(9, 12853) = 4.107, p =
.043), THC (F(9, 11566) = 54.9, p < .001), and amphetamines (F(9, 11566) = 14.9, p <
.001) than women. In contrast, women used benzodiazepines significantly more than men
(F(9, 11599) = 19.7, p = .000). There were no trauma by gender interactions related to
medication adherence or drug use.
Table 12. Relationship between Trauma, Gender, Medication adherence and Drug Use.
Drug (% Positive)

Trauma
F

Buprenorphine

24.3***

Benzodiazepine

21.3***

Gender

Trauma X
Gender

F

F

0.4

0.3

23.6***

0.5

Alcohol

0.2

18.1***

1.1

THC

1.7

54.9***

0.0

14.9***

0.3

Amphetamine

18.1***

Cocaine

18.5***

0.4

2.0

Methadone

0.3

0.1

0.4

Other drug

2.9

4.1

0.4

Opioids All

1.9

1.1

0.1

**p<.01. ***p<.001

Relationship between Covariates and MT Adherence and Drug Use
Medication adherence
There were significant relationships between covariates and measures of
medication adherence and drug use (Table 14). Medication adherence was related to
race (F(9, 11599) = 44.2, p < .001) with whites being more compliant, and treatment
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location (F(9, 11599) = 25.0, p < .001) with those in Massachusetts less compliant. In
regard to ethnicity (F(9, 11599) = 6.9, p = .009), non-Hispanics were significantly more
compliant. Age (F(9, 11599) = 3.3, p = .070) was not related to an increase in
buprenorphine use. Spending more time in care (F(9, 11599) = 798.1, p < .001) was
related to an increase in buprenorphine use. A decrease in the time since last seen (F(9,
11599) = 284.3, p < .001) were significantly related to increased buprenorphine use.
Drug Use
Patients in Massachusetts used more alcohol (F(9, 11562) = 46.3, p < .001), THC
(F(9, 11566) = 70.6, p < .001), cocaine (F(9, 11567) = 136.1, p < .001), and opioids (F(9,
11599) = 26.2, p < .001) more frequently than patients treated in other states. White
patients were less likely to use THC (F(9, 11566) = 12.2, p < .001), cocaine (F(9, 11567)
= 50.1, p < .001), and opioids (F(9, 11599) = 40.5, p < .001), but used amphetamines
(F(9, 11566) = 20.0, p < .001) more frequently. Hispanic patients were significantly less
likely to use benzodiazepines (F(9, 11567) = 19.1, p < .001), alcohol (F(9, 11562) = 8.3,
p = .004), and amphetamines (F(9, 11566) = 26.4, p < .001). However, Hispanic patients
were more likely to use THC (F(9, 11566) = 5.6, p = .018), cocaine (F(9, 11567) = 14.0,
p < .001), and opioids (F(9, 11599) = 16.2, p < .001).
Age was significantly related to medication adherence and most drug measures
except amphetamine (F(9, 11566) = 3.4, p = .065), cocaine (F(9, 11567) = 3.7, p = .056)
and other drugs (F(9, 11567) = 0.5, p = .474). With the exception of benzodiazepines
and amphetamines, an increase in total time care resulted in a decrease in alcohol F(9,
11562) = 17.6, p < .001) , cocaine F(9, 11567) = 390.0, p < .001) , methadone F(9,
11582) = 80.8, p < .001), other drugs F(9, 11599) = 6.2, p = .013) , and opioids F(9,
11599) = 1025.6, p < .001). The time since last seen was significantly related to
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medication adherence and some drug use variables. As the time since last seen increased,
patients decreased their use of buprenorphine (F(9, 11582) = 284.3, p < .001). As the
time since last seen increased, the percent of positive screens of benzodiazepine F(9,
11567) = 67.7 p < .001), alcohol F(9, 11562) = 9.4 p < .001), methadone F(9, 11582) =
19.4, p < .001), and opioids F(9, 11599) = 402.8, p < .001) all increased.
Table 13. Relationship between Medication adherence, Drug Use, and Covariates.
Drug (%
Positive)

Buprenorphine

Race

Location

Age

Ethnicity

Care Time

Last Seen

F

F

F

F

F

F

44.2***

25.0***

Benzodiazepine

5.0

Alcohol

0.3

6.9**

798.1***

284.3***

105.9***

19.1***

0.0

67.7***

46.3***

52.4***

8.3**

17.6***

366.7***

5.6*

3.9*

0.0

0.0

3.3

9.4**

THC

12.2***

70.6***

Amphetamine

19.9***

50.4***

3.4

26.4***

7.3**

2.4

Cocaine

50.1***

136.2***

3.7

14.0***

390.0***

2.1

Methadone

0.5

Other drug

2.3

Opioids

40.5***

0.5
726.5***
26.2***

18.5***
0.5
41.5***

3.5

80.8***

0.2

6.2*

15.5***

1025.6***

19.1***
0.4
402.8***

**p<.01 ***p<.001

AIM 3 – To compare outcomes of Medication treatment (MT) success in patients
with an involvement in the Criminal Justice System (CJS) and patients without
involvement in the CJS.
Relationship between CJS and Treatment Compliance
After including covariates, there were many significant differences in treatment
compliance by CJS. Individuals with CJS had more “no shows” for maintenance visits
(F(9, 12914) = 373.107, p<.001) than individuals without CJS. Similarly, those with CJS
had more “no show” group visits (F(9, 12914) = 24.720, p < 0.001). Individuals with
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CJS had more initial visits, rejoin visits, inductions, and care interruptions (F(9, 12914) =
160.953, p<.001), (F(9, 12914) = 341.315, p<.001), (F(9, 12914) = 307.428, p<.001),
(F(9, 12914) = 182.335, p<.001), respectively, than individuals without CJS. There is
evidence that individuals with CJS have more care interruptions than individuals without
CJS suggesting poorer treatment outcomes (see Table 15).
Although there were no differences in the frequency in cancelling group visits,
individuals with CJS did reschedule their visits more frequently (F(9, 12914) = 118.164,
p<.001). Individuals with a CJS also had more overall maintenance visits (F(9, 12914) =
210.4, p<.001) and total other encounters (F(9, 12914) = 493.6, p<.001). Thus, even after
controlling for the amount of time in care and the time since the last visit, staff are
interacting with patients with a CJS more than individuals without CJS. Finally, there
was also a significant relationship between CJS and total time in care (F(8, 12914) =
743.5, p<.001) and the time since the last visit (F(7, 13445) = 146.2, p<.001).
Relationship between Gender and Treatment Compliance
After including covariates, there were many significant differences in treatment
compliance by Gender (Table 15). Women had more “no show” maintenance visits (F(9,
12914) = 48.5, p < .001), rescheduled visits (F(9, 12914) = 104.6, p < .001), and had
more group cancellations (F(9, 12914) = 10.6, p = .009) than men. Women had more
encounters (F(9, 12914) = 136.7, p < .001) and were less likely to have interruptions in
care (F(9, 12914) = 13.0, p < .001).
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Table 14. Relationship between CJS, Gender, and Treatment Compliance.
Treatment Compliance

CJS
F

Gender
F

CJS X
Gender
F

# no show visits

373.1***

# maintenance visits

210.4***

3.4

0.0

# initial visits

161.0***

0.0

0.7

# rejoin visits

341.3***

1.7

3.2

# induction visits

307.4***

1.3

2.6

1.7

0.1

0.5

9.7**

0.5

1.7

10.6**

5.9

# rescheduled visits

118.1***

104.6***

4.0

# other encounters

493.6***

136.7***

Time since last visits (yrs)

146.2***

10.2**

0.6

# care interruptions

182.3***

13.0***

3.5

Total time in care (yrs)

743.5***

68.7***

6.6

# group visits
# no show group visits
# group cancellations

24.7***

48.5***

7.9**

16.1***

**p<.01. ***p<.001

There were two significant CJS by gender interactions: the number of “no show” visits
and total encounters. There was a difference in the relationship between CJS stats and

frequency of no show maintenance visit between men and women (F(9, 12914) = 8.0, p =
.005)(Figure 6). There was a larger difference between men and women in the number of

no show visits for those with a history of involvement in CJS than for those without a
history of CJS involvement. These data suggest that gender moderates the relationship
between CJS and number of no shows.
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38.00
36.00

Number of No Shows

34.00
32.00
30.00
28.00
26.00
24.00
22.00
20.00
No CJS

CJS
Men

Women

Figure 6. Number of “No Shows” within CJS x Gender Interaction
There was a difference in the number of encounters based on CJS history and
gender (F(9, 12914) = 16.1, p < .001). There was a larger difference between men and
women in the number overall encounters for those with a history of involvement in CJS
than for those without a history of CJS involvement (Figure 7). These data suggest that
gender moderates the relationship between CJS and number of encounters.
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38.00

Number of Encounters

36.00
34.00
32.00
30.00
28.00
26.00
24.00
22.00
No CJS

CJS
Men

Women

Figure 7. Number of Encounters within CJS x Gender Interaction
Relationship between Covariates and Treatment Compliance
There were significant relationships between covariates and several measures of
treatment compliance (Table 16). All relationships between compliance measures and
treatment state were significant with the exception of group cancellations visits. Patients
treated in Massachusetts had poorer compliance on the majority of the variables
examined. For example, patients treated in Massachusetts were more likely to not attend
scheduled maintenance visits (F(9, 12853) = 226.3, p < .001), had more rejoin visits
(F(9, 12914) = 190.8, p < .001), induction visits (F(9, 12853) = 119.2, p < .001), and
more encounters (F(9, 12914) = 40.4, p < .001). However, Massachusetts patients had
more total time in care (F(9, 12915) = 1899.0, p < .001).
Patient race was related to the number of “no show” visits (F(9, 12914) = 7.2, p =
.007), induction visits (F(9, 12914) = 9.5, p = .002), encounters (F(9, 12915) = 7.1, p =
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.00) and total time in care (F(9, 12915) = 30.3, p < .001). Non-whites were more likely
to have more induction visits (F(9, 12915) = 9.5, p = .002) and less total time in care
(F(9, 12915) = 30.3, p < .001). Hispanic patients attended more group visits (F(9,
12914) = 26.9, p < .001) and had more induction visits (F(9, 12914) = 17.0, p < .001).
Hispanic patients also had a significantly higher rate of maintenance visits (F(9, 12914)
= 9.6, p = .002).
Age was significantly related to treatment compliance measures. As age
increased, the number of “no shows” to maintenance visits (F(9, 12914) = 57.8, p <
.001) and the number of rejoin visits (F(9, 12914) = 22.0, p < .001), encounters (F(9,
12914) = 86.2, p < .001) , rescheduled visits (F(9, 12914) = 69.4, p < .001) and
interruptions in care (F(9, 12914) = 49.1, p < .001) decreased. As age increased, the total
time in care (F(9, 12914) = 215.351, p < .001) increased.
With the exception of induction visits, the total time in care was significantly
related to all treatment compliance measures. As the total time in care increased, the
number of no show visits (F(9, 12914) = 1503.3, p < .001), rejoin visits (F(9, 12914) =
465.3, p < .001), group no shows (F(9, 12914) = 3157.9, p < .001), group cancellations
(F(9, 12914) = 455.1, p < .001), rescheduling (F(9, 12914) = 3232.0, p < .001),
encounters (F(9, 12914) = 10743.0, p < .001), and interruptions (F(9, 12914) = 266.6, p <
.001) increased. However, maintenance visits (F(9, 12914) = 39510.2, p < .001) and
groups visits (F(9, 12914) = 11008.4, p < .001) increased as well as total time in care
increased. As total time in care increased, the number of initial visits (F(9, 12914) =
245.6, p < .001) and the time since last seen (F(9, 12914) = 1262.4, p < .001) decreased.
As the time since last seen increased, the total time in care increases (F(9, 12915) =
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1262.4, p < .001), while attending maintenance (F(9, 12914) = 263.5, p < .001) and group
visits (F(9, 12914) = 570.0, p < .001) decreased.
Table 15. Relationship between Treatment Compliance and Covariates.
Treatment Compliance

Race
F

Location
F

Age
F

7.2**

# maintenance visits

1.1

38.2***

2.8

9.6**

# initial visits

0.3

66.1***

3.2

# rejoin visits

3.4

190.8***

# induction visits

9.5**

119.2***

# group visits

3.7

38.2***

# no show group visits

0.2

32.0***

# group cancellations

0.1

1.2

# rescheduled visits

2.2

131.5***

# other encounters

7.1**

40.4***

Time since last visit (yrs)

7.5

727.3***

# care interruptions

0.0

194.6***
1899.0***

30.3***

174.9***

F

# no show visits

Total time in care (yrs)

226.4***

Ethnicit
y

F

Last Seen
F

1503.3***

4.4

39510.2***

263.5***

3.8

245.6***

385.3***

4.6

465.6***

4.9

17.0***

0.1

53.9***

57.9***

26.9***

11008.4***

570.0***

57.8***

4.2

3157.9***

67.1***

0.2

455.1***

69.4***

0.1

3232.0***

22.2***

86.2***

4.6

10742.9***

93.5***

21.9***
0.9

0.1

7.5

6.6

Care Time

5.0

2.9

NA

NA

49.1***

4.5

226.6***

103.5***

215.5***

3.0

NA

1262.4***

**p<.01. ***p<.001

Medication Adherence and Drug Use within CJS
Medication Adherence
CJS, medication adherence, and drug use were evaluated using ANCOVA (Table
17). The CJS group demonstrated greater medication adherence that the non-CJS group.
Consistent with bivariate analyses, after controlling for covariates, patients CJS had a
significantly greater number of positive buprenorphine screens than patients without CJS
(F(9, 11599) = 62.7, p < .001).
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Drug Use
Although more compliant with their medication, patients with CJS had
significantly more benzodiazepine use (F(9, 11567) = 43.4, p < .001), cocaine use (F(9,
11567) = 34.3, p < .001) and other drug use (F(9, 2441) = 4.9, p = .028). Those with CJS
status used methadone (F(9, 11582) = 7.0, p = .008) and opioids (F(9, 11599) = 28.9, p <
.001) less than those without CJS. CJS status was unrelated to THC, alcohol, and
amphetamines,
Gender
There were several significant differences in drug use variables by gender. Men
used significantly more THC (F(9, 11566) = 85.7, p = .000), alcohol (F(9, 11562) = 37.3,
p < .001) and other drugs (F(9, 2441) = 4.0, p = .045) than women, but women used more
amphetamines than men (F(9, 11566) = 21.1, p < .001). There were no significant CJS
by gender interactions.
Table 16. Relationship between Medication adherence/Drug Use and CJS and Gender.

Drugs (% Positive)
Buprenorphine

CJS

Gender

CJS X Gender

F

F

F

62.7***

3.7

0.1

Benzodiazepine

1.0

43.4***

1.2

Alcohol

0.0

37.3***

0.0

THC

6.4

85.7***

0.1

Amphetamine

2.8

21.1***

0.2

Cocaine

34.3***

0.0

0.9

Methadone

6.9

0.2

2.6

Other drug

4.9

4.0

1.5

2.1

0.0

Opioids All

28.9***

**p<.01. ***p<.001
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Relationship between Covariates, MT adherence, and Drug Use
Medication Adherence
There were significant relationships between co-variates and measures of
medication adherence and drug use (Table 18). Medication adherence was related to
race (F(9, 11599) = 43.1, p < .001) and treatment location (F(9, 11599) = 24.1, p < .001).
Non-white and those treatment in Massachusetts were less compliant, while Hispanics
were more compliant (F(9, 11599) = 7.1, p = .008). As Age (F(9, 11599) = 7.3, p = .007)
and total time in care (F(9, 11599) = 738.2, p < .001) increases, the percentage of
buprenorphine also increases. As the time since last seen (F(9, 12914) = 296.0, p < .001)
increased, the use of buprenorphine decreased.
Drug Use
Patients treated in Massachusetts use significantly more alcohol (F(9, 11562) =
45.8, p < .001), THC (F(9, 11566) = 68.2, p < .001), cocaine (F(9, 11567) = 136.4, p <
.001), amphetamine (F(9, 11566) = 52.4, p < .001) and opioids (F(9, 11599) = 24.9, p <
.001) than patients treated in other states. White patients were less likely to use THC
(F(9, 11566) = 11.9, p = .001), cocaine (F(9, 11567) = 51.0, p < .001), and opioids (F(9,
11599) = 39.7, p < .001), but used amphetamines (F(9, 11566) = 19.9, p < .001) more
frequently than non-white patients. Hispanic patients were significantly less likely to use
benzodiazepines (F(9, 11567) = 19.1, p < .001), alcohol (F(9, 11562) = 8.3, p = .004),
and amphetamines (F(9, 11566) = 26.4, p < .001). Hispanic patients had a significantly
higher use of cocaine (F(9, 11567) = 14.0, p < .001), and opioids (F(9, 11599) = 16.2, p <
.001). Methadone, THC, and other drugs did not have a significant relationship with
ethnicity.
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Age was significantly related to medication adherence and most drug measures.
Amphetamines (F(9, 11566) = 2.6, p = .111), cocaine (F(9, 11567) = 1.5, p = .223) and
other drugs (F(9, 11567) = .4, p = .552) did not have a significant relationship to age.
With the exception of benzodiazepines and other drugs, as total time in care increased,
alcohol (F(9, 11562) = 16.6, p < .001) , cocaine (F(9, 11562) = 403.6, p < .001) ,
methadone (F(9, 11582) = 70.6, p < .001) and opioids (F(9, 11599) = 954.0, p < .001) all
decreased in positive screens. The time since last seen was significantly related to a
decrease in medication adherence. As the time since last seen increased (F(9, 11562) =
16.6, p < .001) the percent positive of buprenorphine decreased. As time since last seen
increased, the percent positive screen of benzodiazepines (F(9, 11567) = 62.9, p < .001) ,
alcohol (F(9, 11562) = 9.2, p = .002) , methadone (F(9, 11582) = 19.1, p < .001) , and
opioids (F(9, 11599) = 407.8, p < .001) increased.
Table 17. Relationship between Medication adherence/Drug Use and Co-variates
Drugs (%
Positive)

Buprenorphine

Race

Location

Age

F

F

F

43.1***

24.1***

7.3**

Benzodiazepin

5.0

e
Alcohol

0.3

THC

0.0

Ethnicity
F
7.1

108.3***

19.7***

45.8***

52.1***

8.3**

11.9**

68.2***

372.3***

Amphetamine

19.9***

52.4***

2.5

Cocaine

51.0***

136.4***

1.5

Methadone

0.5

0.4

Other drug

2.3

736.7***

Opioids All

39.7***

24.9***

15.8***
0.3
49.0***

**p<.01. ***p<.001
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5.4

Care Time
F

Last Seen
F

738.2***

296.0***

0.1

62.9***

16.6***

9.2**

7.3**

0.0

26.9***

9.2**

3.4

13.7***

403.6***

1.4

3.5
0.2
15.5***

70.6***

19.1***

6.3

0.6

954.0***

407.8***

Summary of CJS Results
Patients with CJS status are spending more time in care, having more contact with
care providers, and attending more individual maintenance visits. These patients also had
more difficulty attending their scheduled meetings, required more initial and inductions
visits, had more rejoin visits, more encounters, and rescheduled more often than those
without CJS. Patients with a positive CJS status also complied more with medication
treatment utilizing their prescribed buprenorphine more successfully than those without
CJS. This group also used opioids less than the non-CJS group but used more
benzodiazepines and cocaine.
Aim 4. To examine if PTS status moderates the relationship between involvement in
the CJS and Medication Treatment success.
To examine whether or not the interaction of PTSD or Trauma would moderate
the relationship between involvement in the criminal justice system (CJS) and treatment
success, a series of ANCOVA’s were completed. In these analyses, the impact of PTSD
or Trauma, CJS, and the interaction term were examined. Gender was also included as a
between-subjects variable and included in the interactions examined. In addition to a
discussion about significant interactions identified, only relationships between PTSD,
trauma, or CJS and treatment compliance not already presented will be discussed below.
For Aim 3 interactions, the traditional level of significance was used (α = 0.05).
Treatment Compliance
When evaluating the main effects of PTSD and CJS on treatment compliance in
the analyses exploring potential interactions, all main effects were identical to analyses
presented for Aims 1 and Aim 2. Analyses also identified several significant PTSD X
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CJS interactions. The relationships in CJS groups were different for the levels of PTSD
status for the number of initial visits, the number of induction visits, and time since the
last visit (See Table 19).
Table 18. Relationship between Treatment Compliance and PTSD, CJS, and Gender.
PTSD

CJS

PTSD X
CJS

PTSD X
Gender X CJS

F

F

F

F

# no show visits

27.2***

158.4***

0.1

0.2

# maintenance visits

20.1***

82.0***

0.8

1.1

# initial visits

36.5***

21.8***

# rejoin visits

41.4***

150.4***

# induction visits

15.0***

78.7***

Treatment Compliance

# group visits

1.5

# no show group visits

1.5

# group cancellations

0.8

0.1
14.9***
3.1

26.3***
0.0
16.7***

1.8
0.3
3.2

2.8

1.0

0.4

0.5

1.8

1.2

# rescheduled visits

19.1***

66.7***

1.5

1.3

# other encounters

112.6***

255.4***

3.1

0.7

8.1**

36.5***

6.4**

1.6

11.4**

77.7***

0.0

0.5

6.0*

306.7***

0.3

0.6

Time since last visit (yrs)
# care interruptions
Total time in care (yrs)
*p<.05 **p<.01 ***p<.001

When examining for a potential moderating effect of PTSD on the relationship
between CJS and the number of initial visits, there was a significant interaction (F(13,
12849) = 26.3, p = 0.001). Among individuals without a history of CJS, there was a
difference in the number of initial visits based on PTSD status. For those with a history
of CJS, there was no difference in the number of visits based on PTSD status. These data
suggest that PTSD moderates the relationship between CJS and initial visits (See Figure
8).
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Figure 8. Initial visits by PTSD x CJS interaction.
There was a significant interaction of PTSD X CJS on the number of induction
visits (F(13, 12849) = 16.7, p < 0.001). Regardless of PTSD history individuals with a
history of CJS had more induction visits than those without a history of CJS history.
Among those who did not have a history of CJS, patients with PTSD had a higher rate of
induction visits than those without PTSD. These data suggest that PTSD moderates the
relationship between CJS and induction visits (see Figure 9).
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Figure 9. Induction visits by PTSD x CJS interaction.
The relationship between CJS and time since the last visit was different across the
different PTSD groups [F(13, 13365) = 6.4, p = 0.011]. The difference in time since the
last visit was greater between those who had PTSD and those who did not have PTSD
among those without a history of CJS. If there was a history of CJS, there was minimal
difference in the time since the last visits. These data suggest that PTSD moderates the
relationship between CJS and time since last seen (see Figure 10).
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Figure 10. Time since last visit by PTSD x CJS interaction.
Impact of PTSD on the Relationship between CJS and MT/Drug Use

Medication Adherence
When evaluating the main effects of PTSD and CJS on medication adherence and
drug use, the majority of the main effects were identical to what was presented in Aims 1
and 2. However, there were a few exceptions: opioids, THC, and other drugs (see Table
20). The impact of CJS on opioid use was statistically significant in prior analyses. In the
current analysis, the impact of CJS fell below the threshold for significance (F(13, 11595)
= 3.7, p = 0.056). In contrast, although the impact of CJS on THC and other drugs was
not significant in AIM 2 analyses, in the current analyses, individuals with a history of
CJS had less THC use [F(13, 11595) = 4.2, p = 0.041] and more other drug use [F(13,
11595) = 9.3, p = 0.002]. When examining for the potential of a CJS X PTSD interaction
on medication adherence and drug use, the relationship between CJS and medication and
opioids use were different across the PTSD levels. There were no significant PTSD X
CJS X Gender interactions.
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Table 19. Relationship of Medication adherence/Drug Use by PTSD, CJS, and Gender.
CJS

PTSD X
CJS

PTSD X Gender X
CJS

F

F

F

F

Buprenorphine

7.2**

13.1***

Benzodiazepine

65.3***

Drug (% Positive)

PTSD

6.2*

1.2

0.2

0.0

1.9

3.3

0.3

0.2

1.2

THC

11.7**

4.2*

0.0

0.1

Amphetamine

10.6**

2.2

0.5

0.2

Cocaine

12.8***

0.1

0.2

Alcohol

13.7***

Methadone

0.0

0.3

2.6

1.0

Other drug

3.8

9.3**

4.8

0.8

Opioids

8.7**

3.7

5.3*

0.0

*p<.05 **p<.01. ***p<.001

There was a significant interaction of PTSD and CJS on the percent positive
buprenorphine screens [F(13, 11595) = 6.2, p = 0.013]. Among individuals without a
history of CJS, those with PTSD had the higher percentage of buprenorphine positive
screens than those without PTSD (Figure 11). These data suggest that PTSD moderates
the relationship between CJS and medication adherence.
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Figure 11. The % positive for buprenorphine among PTSD x CJS interaction.
Drug Use
There was a significant difference in the relationship between CJS and opioid use
based on PTSD status [F(13, 11595) = 5.3, p = 0.021](Figure 12). There was minimal
difference in the percentage of positive opioid screens for those with a CJS history.
Among those without a history of CJS, those without PTSD had a higher percentage of
positive opioid screens than those without PTSD. These data suggest that PTSD
moderates the relationship between CJS and percent positive of opioid screens.
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Figure 12. The % positive for opioids by PTSD x CJS interaction.
Aim 5. To examine if trauma status moderates the relationship between involvement
in the CJS and Medication Treatment success.
Impact of Trauma on the Relationship between CJS and Treatment Compliance

When evaluating the main effects of trauma and CJS among treatment compliance
indicators, most of the main effects were as described in AIMS 1 and 2. The only
exception was care interruptions. Although in AIM 1 there was a significant relationship
between Trauma and care interruptions, in the current analyses, this relationship was no
longer significant (F(13, 12849) = 2.0, p = .153)(See Table 21). When examining for CJS
X trauma interactions, several were identified: “no show” visits, initial visits, induction
visits, group visits, number of encounters, and time since the last visit. There were also
several trauma X CJS X gender interactions: “no show” visits, maintenance visits, and
the total number of encounters.
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Table 20. Relationship of Treatment Compliance by Trauma, CJS, and Gender
Trauma

CJS

Trauma X CJS

Trauma X CJS
X Gender

F

F

F

F

19.2***

277.5***

106.6***

105.6***

# initial visits

7.6**

26.1***

# rejoin visits

36.7***

201.7***

0.3

1.3

# induction visits

61.7***

112.9***

11.6**

2.7

1.8

13.3***

0.0

Treatment Compliance

# no show visits
# maintenance visits

# group visits

0.7

# no show group visits

1.9

# group cancellations

1.3

22.1***
3.6

17.9***
0.0
47.0***

5.3*
11.0**
0.0

2.2

0.2

2.5

0.3

3.5

0.6

# rescheduled visits

41.5***

81.3***

# other encounters

256.5***

371.2***

28.4***

9.1**

Time since last visit (yrs)

163.7***

19.0***

29.3***

0.1

2.0

88.8***

1.4

0.0

314.1***

399.9***

2.4

0.8

# care interruptions
Total time in care (yrs)

*p<.05 **p<.01. ***p<.001
There was a difference in the relationship between CJS and the number of “no
show” visits by trauma status (F(13, 12849) = 17.9, p < 0.001). Patients with trauma and
a history of CJS had a higher rate of ‘no show’ visits than patients without PTSD and a
history of CJS (Figure 13). These data suggest that trauma moderates the relationship
between CJS and “no show” visits.
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Figure 13. Total # of no show visits within trauma x CJS

Evaluation of the interaction of Trauma and CJS on the number induction visits,
identified a significant effect (F(13, 12849) = 11.6, p < 0.001). Individuals with CJS had
a high rate of encounters regardless of trauma history. In contrast, if there was not a
history of involvement with CJS, individual with a trauma history had more induction
visits, than those with a trauma history. These data suggest that trauma moderates the
relationship between CJS and induction visits (see Figure 14).

105

1.10
1.05

Number of Inductions

1.00
0.95
0.90
0.85
0.80
0.75
0.70
0.65
0.60
No CJS

CJS
No Trauma

Trauma

Figure 14. Total # of induction visits within trauma x CJS.
There was also a significant trauma X CJS interaction on the number of
encounters (F(13, 12849) = 28.4, p < 0.001). The relationship between CJS and the
number of encounters was greater for those with a history of trauma than those without a
history of trauma. These data suggest that Trauma moderates the relationship between
CJS and the number of encounters (see Figure 15).
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Figure 15. Total # of encounters within trauma x CJS.
There was a difference in the relationship between CJS status and time since last
visit (F(13, 12849) = 29.3, p < 0.001) based on trauma history group membership. If a
patient had a history of trauma, time since a patient was last seen was virtually identical
between CJS groups. If a patient had a history of trauma, patients who also had a history
of CJS had been seen more recently than individuals without a history of CJS. These
data suggest that trauma moderates the relationship between CJS and time since last seen
(Figure 16).
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Figure 16. Time since last visit by trauma x CJS interaction.
There was a difference in the relationship between CJS status and initial visit
(F(13, 12849) = 47.0, p < 0.001) based on trauma history group membership. For those
with a trauma history, there is minimal difference in initial visits based on CJS status with
those with a CJS status being slightly lower. Among those without a trauma history,
those with a history of CJS had more initial visits than patients without a history of CJS.
These data suggest that trauma moderates the relationship between CJS and number of
initial visits (Figure 17).
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Figure 17. Total # of initial visits by trauma x CJS interaction.
There was a difference in the relationship between CJS status and group visits
(F(13, 12849) = 13.3, p < 0.001) based on trauma history group membership. For those
with a trauma history, there is a difference in group visits based on CJS status with those
with a CJS status being lower. Among those without a trauma history, those with a
history of CJS had more group visits than patients without a history of CJS. These data
suggest that trauma moderates the relationship between CJS and number of group visits
(Figure 18).
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Figure 18. Total # of group visits by trauma x CJS interaction.
Impact of Trauma on the Relationship between CJS and MT Adherence/Drug Use

Medication Adherence
When evaluating the main effects of trauma and CJS among medication
adherence and drug use, all of the main effects were as described in AIMS 1 and 2. In
addition, there was also a significant trauma X CJS interaction for buprenorphine and
opioids (Table 22). There were no significant trauma X CJS X gender interactions.
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Table 21. Relationship between Medication adherence/Drug Use by PTSD, CJS, and
Gender.
Drug (% Positive)

Trauma
F

CJS

Trauma*CJS

Trauma*CJS*Gender

F

F

F

15.6***

0.0

Buprenorphine

9.8**

12.1**

Benzodiazepine

22.5***

1.7

1.7

0.1

Alcohol

0.6

0.7

1.7

0.2

THC

2.3

2.9

0.2

0.2

2.1

0.4

0.0

1.4

1.3

Amphetamine

17.2***

Cocaine

17.2***

24.5***

Methadone

0.0

2.4

0.6

0.1

Other drug

2.9

4.4*

0.5

0.0

Opioids All

0.0

4.8*

11.0**

1.5

*p<.05 **p<.01. ***p<.001

As mentioned, there was a significant impact of trauma on the relationship
between CJS and medication adherence. Regardless of CJS status, patients with a history
of trauma had high rates of medication adherence (F(13, 11595) = 15.7, p < 0.001).
Among those without a history of trauma, patients without a history of CJS had lower
rates of medication adherence than patients without a history of CJS. These data suggest
that trauma moderates the relationship between CJS and number of and percent of
positive buprenorphine screens (Figure 19).
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Figure 19. The % positive for buprenorphine within CJS x Trauma interaction.
Drug Use
There is a significant difference between CJS and opioid use based on Trauma
status (F(13, 11595) = 11.0, p = 0.001). For those with a trauma history, there is minimal
difference in opioid use based on CJS status. Among those without a trauma history,
those without a history of CJS had more opioid use than patients with a history of CJS.
These data suggest that trauma moderates the relationship between CJS and number of
encounters (Figure X). These data suggest that trauma moderates the relationship
between CJS and number of encounters (Figure 20).
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Figure 20. The % positive for opioids by CJS x Trauma interaction.
Influence of Gender on the Relationships between Trauma and CJS and Outcomes
Exploring the influence of gender on the relationships between trauma and CJS
on outcomes did not identify many significant interactions. Only the number of “no
show” visits and the number of maintenance visits were significant. There was a
significant impact of gender on the interaction of trauma and CJS on maintenance visits
[F(13, 12849) = 11.0, p = 0.001]. When examining the impact on trauma and CJS on the
number of maintenance visits for men is different than for women. For men, those with a
history of trauma have more maintenance visits regardless of CJS history (Figure 21).
For women, the impact of CJS history appears to have more of an impact on the overall
number of maintenance visits attended (Figure 22). These data suggest that gender
moderates the relationships between trauma, CJS, and maintenance visits.
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Figure 21. Maintenance visits by CJS and Trauma for Men.
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Figure 22. Maintenance visits by CJS and Trauma for Women.
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Figure 23 and 24 presents the data for the number of “no show” visits by trauma
and CJS history by gender. There was a significant interaction of gender, trauma, and
CJS status for the number of “no show” visits (F(13, 12849) = 5.3, p = 0.021). There was
minimal different in the number of “no show” visits based on trauma history for men.
Both trauma groups had more “no show” visits if there was a history of involvement with
CJS than if there was no history of CJS. For women, there were minimal differences
among those without trauma based on CJS status. If there was a history and CJS and
there was also a history of trauma, there was a high rate of “no show” visits. These data
suggest that gender moderates the relationships between trauma, CJS, and “no show”
visits.
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Figure 23. “No show” visits by CJS and Trauma for Women.
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Figure 24. Figure X. “No show” visits by CJS and Trauma for Men.
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CHAPTER 5
DISCUSSION
This chapter provides a discussion of the findings of the study. This study set out
to understand the impact that post-traumatic stress (PTS), trauma, and an involvement in
the criminal justice system has on the outcomes of opioid use disorder treatment. This
study utilized treatment compliance outcomes, medication adherence outcomes, and drug
use as the findings This study sought to answer three major questions:
1. Do those patients with PTSD has less successful treatment outcomes than
those without PTSD?
2. Do those patients with an involvement in the criminal justice system have less
successful treatment outcomes than those without an involvement in the
criminal justice system?
3. Does PTSD/Trauma moderate the relationship between the having a criminal
justice status and treatment outcomes?
Summary of Results
Table 23 provides a summary of the relationships between each of the
independent variables (PTSD, trauma, criminal justice status, and gender) among both the
treatment/medication adherence indicators and drug use indicators. Table 24 provides a
summary of the results from interaction analyses between all treatment compliance
indicators and drug use by independent variables by gender and CJS.
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Table 22. Summary of relationships by Treatment compliance and Drug Use
Treatment
Compliance

PTSD

Trauma

CJS

+
+
+

+
+
+

+
+
+

+ (W)
-

+
+
-

+
+
-

+
+
-

+ (M) (CJS)
+ (W) (CJS)

+
+
+

+
+
+

+
+
+

+ (W)
+ (W)

-

-

+

+ (W) (Trauma/CJS)

Time since last visits (yrs) +

+

+

+ (M) (CJS)

# no show visits
# initial visits
# rejoin visits
# induction visits
# care interruptions
# group cancellations
# rescheduled visits
# maintenance visits
# other encounters
# group visits
# no show group visits

Gender

+
PTSD

+
+
Trauma CJS

+ (W)
Gender

THC

+
+
+

+
+
-

+
-

+ (W)
+ (M)

Amphetamine

+

+

-

+ (W) (Trauma/ CJS)

Alcohol

-

-

-

+ (M)

Cocaine

+
+
-

+
-

+
-

-

Total time in care (yrs)

Medication/Drug Use
Buprenorphine
Benzodiazepine

Opioids All
Methadone

+ = a relationship between treatment compliance or drug use and IV’s
- = no support of a relationship between DV and IV
Unless otherwise noted, +/- apply to all PTSD, Trauma, and CJS groups
M = men, W = women,
 = highest #/percent
Other drug
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Table 23. Summary of interactions by Treatment/ compliance and Drug Use
Treatment
Compliance
# no show visits

PTSD Trauma
x CJS x CJS

PTSD
x
Gender

Trauma
x
Gender

CJS x
Gender

PTSD x
Gender
x CJS

-

-

+ (W)

+ (W)

-

+

Trauma x
Gender x
CJS
+ (M w/CJS)
(W w/CJS)

# initial visits

+

-

-

-

-

-

-

# rejoin visits

+
-

+
-

-

-

-

-

-

# group cancellations -

-

-

-

+ (W)

-

-

-

-

-

-

-

-

-

+ (M/Trauma)

# induction visits
# care interruptions
# rescheduled visits
# maintenance visits
# other encounters

(W w/CJS)

-

+

-

+ (W)

+ (W)

-

+ (M w/CJS)
(W w/CJS)

# group visits

-

-

-

-

-

-

-

# no show group
visits

-

-

-

-

-

-

-

Time since last visits (yrs)

+

-

-

-

-

-

Total time in care
(yrs)

-

-

-

-

-

-

-

Medication/Drug
Use

PTSD Trauma
x CJS x CJS

Buprenorphine

+

Benzodiazepine
THC
Amphetamine
Alcohol
Cocaine
Opioids All
Methadone
Other drug

+

PTSD Trauma
x
x
Gender Gender
-

-

PTSD x
Trauma x
Gender
Gender X
X CJS
CJS
-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

+
+

+
-

-

-

-

-

-

+ = a relationship between treatment compliance or drug use and IV’s
- = no support of a relationship between DV and IV
Unless otherwise noted, +/- apply to all PTSD, Trauma, and CJS groups
M = men, W = women,  = highest #/percent
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CJS x
Gender

The Impact of PTSD on Treatment Compliance
Patients with a positive PTSD status were not as successful in meeting treatment
compliance indicators as those without PTSD. It was hypothesized that those patients
with PTSD would have a lower rate of attending scheduled individual and group visits.
Furthermore, it was thought that these patients would not attend meetings without
notifying center staff, that they would reschedule and cancel group visits more often,
have more encounters with staff, leave care more often and need more initial, inductions,
and rejoin visits. Those patients with an increase in PTSD symptoms did reveal less
treatment compliance throughout many treatment indicators and increased drug use. It
was hypothesized that those patients with PTSD would have a lower rate of adherence to
buprenorphine and an increase in other drug use, especially opioid use. There is more
than adequate evidence demonstrating that buprenorphine treatment contributes to higher
retention in treatment, lower opioid use, lower other substance use, and lower mortality
(D’Onofrio et al., 2017; Mattick, Breen, Kimber, & Davoli, 2014; Parks Thomas et al.,
2014). Yet, despite this evidence, these findings are not evident when considering
evidence of PTSD or a history of trauma. Patients within this study with PTSD are more
buprenorphine adherent than those without PTSD yet are also having higher percentages
of opioid and other substance use and failing to meet treatment compliance indicators
highlights the major issue these patients are struggling to stay med compliant and their
immediate needs are not being met.
Patients with PTSD did not appear for scheduled individual visits more frequently
than those without PTSD. It has been noted previously that treatment for co-occurring
SUD/PTSD has the potential for high drop-out rates and a reduction in treatment due to
the stress of reliving traumatic events (Gielen, Krumeich, Havermans, Smeets, & Jansen,
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2014; Kehle-Forbes et al., 2016). The differences in practitioner’s ability to effectively
counsel based on an integrated therapy for both SUD/PTSD may also contribute to some
patients feeling not fully supported (Killeen, Back, & Brady, 2015) and thus not attend
scheduled individual meetings. Surprisingly, there were no differences noted with
regards to any of the group visit indicators. The number of group visits cancellations,
the amount of ‘no show’ visits, and the number of group visits overall did not
significantly differ from those without PTSD. This may be that those feel more
supported by peer-oriented groups. There is the additional motivation for patients to
remain compliant with group visits as this is required for them to be prescribed MT by
clinicians.
Unexpectedly, those with PTSD attended more maintenance visits than those
without PTSD. This may be attributed again to either a higher gestalt rating from the
provider and needing a greater degree of follow-up as well as a desired coping
mechanism to continue medication treatment. Though their results are based on a
considerably smaller sample size than this study, this outcome is contrary to Norman,
Tate, Wilkins, Cummins, & Brown (2010). They determined that there were no
differences between those with and without PTSD and their attendance at maintenance
visits.
It was expected that those patients with PTSD would have a shorter time since last
seen and have a longer duration in care. It was found that these patients have a shorter
time since last seen. Since patients are having more encounters with staff, their time
between visits should be shorter and indicative of increased risk for relapse. It is possible
that the clinical staff (advance practice nurses and physicians) placed them on a higher
level of intervention which would result in more frequent visitation. One can view this as
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potentially beneficial for them as it does allow them the opportunity to seek help and
interact with staff more frequently.
The patient’s total time in care increases with PTSD. As this is cumulative time
in treatment, when accounting for the fact that those with PTSD have an increased
number of initial visits, rejoins, inductions, interruptions, and reschedules, this has the
potential to add a significant amount of time to their overall treatment. The significant
need for long term treatment for those with co-occurring PTSD and OUD has been noted
by Mills et al. (2018) at 11-years follow-up, 46% of their similar cohort was still in
treatment for their SUD.
It was hypothesized that those patients with PTSD would have a lower rate of
adherence to buprenorphine and an increase in other drug use, especially opioid use.
There is more than adequate evidence demonstrating that buprenorphine treatment
contributes to higher retention in treatment, lower opioid use, lower other substance use,
and lower mortality (D’Onofrio et al., 2017; Parks Thomas et al., 2014). Yet, despite this
evidence, these findings are not evident when considering evidence of PTSD or a history
of trauma. The fact that those patients with PTSD in this study are more buprenorphine
adherent than those without PTSD yet are also having higher percentages of opioid and
other substance use, and meeting treatment compliance indicators highlights the major
issue these patients are struggling to stay med compliant and their immediate needs are
not being met. As their PTSD and trauma history are influencing their feelings of safety,
possible loss of control, heightened anxiety levels, etc., they may not be fully ready to
commit to full treatment compliance (US Department of Health and Human Services,
2014).
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PTSD and Buprenorphine
Surprisingly, patients with PTSD were more adherent to their prescribed
buprenorphine regimen than those without PTSD. Past research has shown that those
with PTSD have had decreased adherence to buprenorphine (Kumari et al., 2016). This
could be related to their increased number of encounters and shorter time since last seen.
As they are seen more frequently by staff, the motivation to continue their medication
treatment increases. As this is the philosophy of this particular treatment center, this is
validation that increasing visits and contact with staff when risk is elevated, has the
benefit of increased medication adherence. This is supported by previous work by
Schacht, Brooner, King, Kidorf, & Peirce (2017) who found that the longer their
participants stayed in treatment they reduced their positive urine screens for drugs and
had less severe symptoms for those with PTSD. Similarly, Meshberg-Cohen, Black,
DeViva, Petrakis, & Rosen (2019) determined that those veterans in treatment for
PTSD/OUD treatment that received concurrent therapy for trauma while receiving
buprenorphine, resulted in an increased length of retention in their program with overall
greater treatment success as a result.
PTSD and Drug Use
Those with PTSD did have a higher rate of opioid use than those without PTSD.
These results suggest that while those patients with PTSD were still motivated to
maintain their buprenorphine adherence, they still struggled to refrain from opioid use.
As discussed in chapter 2, those patients with PTSD typically have a higher rate of opioid
use than those without PTSD (Meier et al., 2014). This outcome is contrary to previous
findings by Mills et al. (2018) that found at follow-up to treatment no baseline difference
in heroin use based on PTSD status.
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While this study used an amalgam of opioids as one indicator, which included
prescription and non-prescription opioids, Meier et al. (2014) had similar findings in their
study based on prescription opioids and the severity of other substance use among those
with PTSD while in treatment. In contrast to previous findings by Kumari et al. (2016),
those with PTSD having used opioids during treatment also had a lower compliance with
buprenorphine.
Impact of Trauma on Treatment Compliance
Similar to the PTSD group, those patients with a history of trauma did show less
treatment compliance throughout the same treatment indicators as well as increased drug
use same as the PTSD group. Those patients with a history of trauma had a lower rate of
attending scheduled individual and group visits. Consequently, they also did not attend
meetings without notifying center staff, they rescheduled and cancelled group visits more
often, had more encounters with staff, left care more often and needed more initial,
induction, and rejoin visits. As mentioned earlier as regards PTSD, the same is valid for
patients with trauma histories. Although they are staying more medication adherent with
buprenorphine than those without trauma histories, they are also using opioids and other
substances more, and missing the same treatment compliance indicators as those with
PTSD. This group is similarly struggling to stay within the program of medication
adherence and treatment compliance.
Similar to those patients with PTSD, those with a history of trauma, had the exact
same treatment compliance results in terms of significant relationships between trauma
and treatment indicators. Based on prior research, it is assumed that many of those with a
trauma history in this study are also underdiagnosed as having PTSD (Elhai et al., 2012;
Zimmerman & Mattia, 1999). This may provide the explanation as to why these two
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groups had the same results. If in fact those with trauma also had undiagnosed PTSD,
They may be experiencing similar symptoms and their specific needs in respect to
needing trauma-informed care are simply not being met with just buprenorphine
treatment.
Impact of Trauma on Medication Adherence and Drug Use
Trauma and Buprenorphine
Similar to the PTSD group, those with a history of trauma they were in fact more
adherent to their scheduled medication than those without a history of trauma. While it
was hypothesized that those with a history of trauma would also not be adherent to their
buprenorphine, similar to the PTSD group, the reasons for this result are the same for the
PTSD group. Since those with a history of trauma were also less treatment compliant in
terms of visits, they would have had more interaction with staff and would have been
more focused and motivated to stay adherent to their medication schedule knowing they
would be seen more frequently by treatment center staff.
Trauma and Drug Use
While those with a history of trauma had similar drug use as those with PTSD,
there were two differences. Those with a history of trauma did not have a significant
relationship to opioids and THC. Reasons for this may be that while this group has
experienced a traumatic event, they may not have developed a post-traumatic response
and as a necessity tried to reduce symptoms associated with the sequelae of trauma. It
has been discussed in other studies that those affected in a traumatic way will at times use
opioids and THC more as a means to self-medicate to try to reduce symptoms of anxiety
related to trauma (Hassan, Foll, Imtiaz, & Rehm, 2017; Meshberg-Cohen et al., 2019;
Saunders et al., 2015). This may not be the case for this particular group of patients.

125

The Impact of CJS on Treatment Compliance
Those patients with CJS displayed less treatment compliance throughout the same
treatment indicators as well as increased drug use similar to the PTSD/trauma groups.
This was an expected outcome. As was discussed in chapter 2, those with an involvement
in the criminal justice system often suffer from PTSD and experience trauma during their
incarceration experience. Additionally, those with CJS are also at a higher risk to enter
incarceration having already experienced trauma and/or having a diagnosis of PTSD
(Anderson, Geier, & Cahill, 2016; Harner, Budescu, Gillihan, Riley, & Foa, 2015;
Kouyoumdjian et al., 2015). Similar to the PTSD/trauma groups, it was hypothesized that
those patients with CJS would have a lower rate of attending scheduled individual and
group visits.
Similar to those patients with PTSD/Trauma, those with CJS, had the exact same
treatment compliance results in terms of significant relationships between CJS and
treatment indicators. One difference from the other two predictors was the addition of a
significant relationship between CJS and no shows for group visits. Upon further
evaluation, even when controlling for age, race, time since last seen, total time in care,
location, and ethnicity, there was no evidence of moderation between PTSD or trauma on
CJS and group no shows. A possible explanation for this difference may be that some
people with criminal justice involvement that are in treatment SUD find it hard to share
in group therapy situations and may prefer individualized treatment (Owens, Chen,
Simpson, Timko, & Williams, 2018).
The inclusion of an interaction term also revealed a moderating effect of PTSD on
CJS with regards to initial and induction visits. It was not apparent in the literature that
this relationship was examined previously. One potential explanation is that again as
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patients with CJS are also managing their PTSD symptoms, it may be that the PTSD
itself is having an effect on their ability to stay focused in treatment and thus leaving with
more frequency and having to have additional initial and induction visits similar to that of
main effects relationship of PTSD to treatment compliance.
Impact of CJS on Medication Adherence and Drug Use
CJS and Buprenorphine
Unexpectedly, those with CJS were more adherent with their buprenorphine
regimen. It was hypothesized that again, the CJS group, like that of the PTSD/trauma
groups would not be as adherent to their buprenorphine as the non-CJS group. This may
be due to a motivation to stay free of drugs and committed to their treatment due to the
consequences of having to return to incarceration if they are found to be drug positive.
As those with CJS increased the total time in care, there is also a significant decrease in
opioid use. This finding is consistent with Gordon et al. (2015) and research on parolees
and probationers who were in medication treatment for OUD.
CJS and Drug Use
Another unexpected result was that the CJS group had less drug use than expected
compared to the non-CJS group especially as it pertains to opioids and methadone. The
CJS group had significantly less percentage of opioids and methadone than the non-CJS
group. This again suggests that not only is there a motivation to stay free from
incarceration, but potentially the preference for more may be protective from drug use.
This finding supports observations by Fox et al. (2015) who conducted a small number of
interviews with patients who had previously been incarcerated and were either presently
in treatment for OUD or had been in the past. They found that these patients preferred
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medication treatment over abstinence-based recovery. Furthermore, they not only
preferred medication treatment, but also favored buprenorphine over methadone.
CJS was evaluated with PTSD and trauma as potential moderates and found that
both PTSD and trauma moderated that effect that CJS had on increasing buprenorphine
adherence and a slightly higher use of opioids over the non-PTSD and non-trauma
groups. As mentioned previously, these results mirror the PTSD and trauma main
effects. The most interesting of these results is that of the moderation effect on opioids.
While those with PTSD but without CJS are using opioids significantly less than the nonPTSD group as in the main effect, once CJS is added, there is a significant reduction in
use of opioids for the non-PTSD group which is concurrent with the previous evaluation
of CJS main effects, but the PTSD group slightly increases their opioid use. This again
shows that even with the motivation of staying free of opioids in the CJS group, this isn’t
enough to override the need to still use opioids once PTSD is added. This is additionally
another measure that needs to be accounted for during and before release from
incarceration. If this group had been evaluated for both OUD and PTSD and trauma at
the same time on admission and treated appropriately, we may see that the CJS with
PTSD group stays at the same level of opioid use.
Impact of Gender on Treatment Compliance
When evaluating treatment compliance by gender, there were noted differences
between men and women. Women, similar to those with PTSD and histories of trauma,
are being underserved within this treatment modality. Again, while there was no
difference in medication adherence, there were still more instance of failed treatment
compliance, and other drug use. As noted previously, women had the highest
percentages of PTSD and trauma, which may contribute to some of these issues.
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Gender was combined with trauma to evaluate moderating effects and found that
trauma did moderate the effects of no-show visits, rescheduling, and more encounters,
with women always having higher rates than men. A similar interaction was evaluated
for CJS and gender and found that the effects of CJS on gender. With many people
within CJS groups experiencing trauma before and during incarceration, this could be the
reason for the same effect. It is still apparent that women are struggling as well and need
more directed care with a focus on trauma specific treatment.
There were noted differences in gender as a predictor than the other three
predictors (PTSD, trauma, and CJS). There were no gender differences in the attendance
to maintenance visits, which is similar to findings by McHugh et al. (2013) that found no
gender differences in attendance at treatment sessions. Women spent more time in care
than men which is supported from previous research (Evans et al., 2015). Women were
more likely to have more no shows, no show group visits, cancel group meetings in the
CJS group, and reschedule visits more. One explanation for this may simply be social
functioning of women compared to men. A study of gender differences in OUD
treatment by Bawor et al. (2015) revealed that while women were less likely to be
employed then men, they were three times as likely to be caring for children. Another
explanation could be that as 13.4% women had a PTSD status and 17.0% of women had a
trauma history, there may be a reluctance to attend both individual and group treatment
sessions for fear of stigma, anxiety, or embarrassment. However, this may not overtly
affect their ability to maintain the same use of buprenorphine and use of opioids as men.
As Sokol, LaVertu, Morrill, Albanese, & Schuman-Olivier (2018) pointed out after a
large systematic review of studies based on group therapy based treatments for OUD
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patients, there does not appear to be a large-scale significance for outcomes based on
group therapy for those with OUD.
Impact of Gender on Medication Adherence and Drug Use
Evaluating medication adherence and drug use by gender revealed differences
between gender and the three other predictor variables.
Gender and Medication Adherence
The relationship between gender and buprenorphine adherence was not
significant.
Gender and Drug Use
Women showed an increased use of benzodiazepines and amphetamines (among
trauma and CJS groups) which is consistent with previous findings (Bawor et al., 2015).
The use of amphetamines if particularly alarming as research by Evans et al. (2015)
revealed the concurrent use of amphetamines and opioids contributes to an increase in the
hazard risk for death for women that are in treatment for OUD.
Men had a significant increased use of THC and alcohol. Bawor et at. (2015) also
determined that THC use was higher in men, however, they did not determine any gender
differences for alcohol. This present study found alcohol to be higher by positive urine
screen in men.
Application to Theory
As previously noted in chapter 2, Lazarus and Folkman’s (Lazarus & Folkman,
1984) Transactional Stress theory informed the study by providing a framework to view
stress, appraising stress, and coping with stress as a goal focused toward long-term
adaptation to stress. These stress indicators were not measured, but rather assumed under
the operationalized variables of PTSD, trauma, and CJS. The initial reason for choosing
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this theory was based on the prevalence within the literature suggesting that a large
proportion of those with an OUD were using opioids and other substances as a way to
reduce stress or in response to stress from trauma. The transactional stress theory
appeared to fit well within the realm of opioid use while managing PTSD, a history of
trauma, a past incarceration experience, or the presence of all three. As discussed in the
literature review, all three of these situations has the ability to create a larger stress
dynamic for the patient through an increase in anxiety and other psychosomatic responses
to stress. Lazarus and Folkman regard the ideal coping method as a series of appraisals
followed by conscious decision making to react in an adaptive way.
The chronic brain disease model of addiction suggests that those with OUD using
opioids and other substance continue to disrupt decision-making and self-control neural
processes within the brain (Baler & Volkow, 2006; NIDA, 2018). This disruption makes
it more difficult to make pertinent decisions related to controlling one’s use of substances
in relation to events in their life (Smith, Mattick, Jamadar, & Iredale, 2014; Volkow &
Morales, 2015). This is similar to the transactional stress theory that theorizes a stress
response to a specific event in life. As hypothesized in Chapter 2, for those with PTSD,
CJS, or trauma, a successful coping strategy would be for those patients to employ a
problem-based method to solve their stressful situation. The optimal end result would be
free of drug use as a consequence that benefits not only short-term gains but can
cumulatively function as building a long-term physical and cognitive response to stress
without opioids or other drug use.
The transactional stress theory is complementary to the chronic disease model as
viewed through this study. Framing the study through transactional stress theory, it
suggests that potentially, the patient’s brain is learning to sustain itself with markedly less
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opioids with the use of buprenorphine, the patient is also making repeated appraisals
which neurobiologically is redefining neural connections to learn to cope more
effectively without opioids (Volkow, Koob, & McLellan, 2016). Within this study
though, for those with PTSD and trauma, as an example, we can view two responses to
stress. The increase in maintenance visits for those with PTSD and trauma, than those
without, could be viewed as evidence that when combined with medication treatment
(MT) there is an adaptive coping strategy being employed in light of the stress, which
will hopefully lead to long-term adaptation. However, there is also the increase of use of
opioids for those with PTSD and trauma than those without. This is reflective of poor
decision making as a result of assumed stress and maladaptive coping strategies utilized
by patients with PTSD, trauma, and a CJS.
In regard to treatment compliance, all three predicator variables have similar
significance and direction in terms of compliance indicators. For those three predictor
groups, missing maintenance visits without notice, leaving treatment and then rejoining
and having to have more initial and induction visits, are all consequences of appraisals
based on stress and control. Those visits present several possibilities of stress for the
patients that begins the process as a causal antecedent. Failing to meet those compliance
indicators could be because the person is worried about having to provide a urine sample
knowing it will produce positive results for drug use.
An explanation for this is that those patients are anxious about attending an
individual session with a provider and having to talk or re-live a traumatic experience.
There could be an element of shame and stigma that is holding a patient back from
attending these visits. These are results of false or negative appraisals that allow the
patient to revert back to place of wanting to maintain control for fear of harm or trauma.
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As these patients miss more meetings and need to induct themselves to treatment, we can
view their subsequent attendance as a positive appraisal that have resulted in their ability
to attend these visits and to be safe and unharmed.
Those patients with PTSD/trauma/CJS showed maladaptive coping skills in their
use of opioids, THC, cocaine, benzodiazepines, and amphetamines. It is clear that upon
primary appraisals of stress during their treatment they have still reverted back to using
opioids or other drugs. However, they are still maintaining adherence to their
buprenorphine treatment more than those without PTSD/trauma/CJS, which over time
may allow these groups of patients to benefit from long-term effects of continuing
treatment with buprenorphine, while reducing their use of opiates and other drugs. This
has the potential benefit of long-lasting recovery, improved mental health, reduced
mortality, improved social functioning through long-term adaption to life stressors.
One particular example of Lazarus and Folkman’s concept of problem-focused
coping is the success of the CJS group to use opioids less than those without CJS and
have a higher rate of buprenorphine use. Re-entering their communities after
incarceration increases stress and risk for relapse (Binswanger et al., 2012; Wakeman,
2017). When encountering stress in their lives, these individuals appear to be attending
to the situation from a problem-focused position. This process may include cognitively
appraising the consequences of using opioids again and not adhering to their medication
treatment, which may result in their return to incarceration (Matusow et al., 2013). This
increased vigilance may offer the patient the needed focus to problem solve effectively,
which is enhanced due to the addition of medication treatment which will also reduce
cravings and additional reduction of symptoms from reduced opiate use.
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This raises more questions if looking at transactional stress within the realm of a
chronic brain disease model for addiction for those CJS patients. If this is a lack of
adaptive coping, self-control, and inappropriate decision making, how is it that those
within the CJS group are able to override that and not rely on opioids? Applying this
theory to CJS patients in this manner supposes the implication of psychological stress on
those patients when in fact those may be simply weighing a cost-benefit analysis of
staying opioid free to stay out of jail or prison. Theories and concepts of motivation,
control, community risk factors, or punitive justice/treatment policies warrants further
study especially in light of the findings of this study.
Implications for Nursing Practice
As this study has confirmed, those with PTSD, a history of trauma, and a past
involvement in the criminal justice system, can have very significant and lasting
consequences that impact treatment compliance and medication adherence for those with
OUD. The Substance Abuse and Mental Health Services Administration (SAMHSA)
states that it is imperative that treating trauma should be a primary goal when treating a
person with co-occurring OUD/PTSD or history of trauma (US Department of Health and
Human Services, 2014). Advance practice nurses and physicians in various practices are
not accepting enough patients even when they have not met their designated capacity to
take on patients utilizing buprenorphine (Huhn & Dunn, 2017).

Presently, there is a

need for nurses and nurse practitioners to care for those with OUD and co-occurring
mental health disorders. The American Association of Nurse Practitioners (AANP)
educates Nurse Practitioners on the practices of prescribing MT to patients and lowering
the risk of overuse of opioids for patients. The education outline on their website is
titled: Opioid Risk Evaluation and Mitigation Strategy Resources (REMS). Of concern is
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that this lacks any mention of assessing for trauma, PTSD, or past experiences that may
involve trauma such as a criminal justice history, veteran, or refugee status as potential
risks (AANP, 2018).
If nurse practitioners and nurses are to be trained to successfully to treat those
with an OUD, they need to assimilate a model of trauma-informed care for their patients
and not only assess prior opioid use, but past trauma. This omission of treating those
with trauma is not only absent here but also with the American Society of Addiction
Medicine (ASAM). In the published clinical guidelines of practice for the ASAM, the
only mention of trauma or PTSD is in relation to assessing for other co-morbid diagnoses
during the history and physical (American Society of Addiction Medicine, 2015). While
this is a positive step, the manual lacks any mention of what the clinician, nurse, or team
member should do if the patient screens positive for these and how to then develop a
course of treatment that reflects these potential risks to reduced treatment compliance.
Nurses are poised to be at the forefront of addiction treatment, especially as it
relates to those with OUD that also have a history of trauma. As Moller & McLoughlin
(2013) assert, the fundamental core nursing philosophy is congruent with that of traumainformed care. Moller & McLoughlin (2013) remind us that the American Nurses
Association (ANA) definition of nursing practice is:
Nursing is the protection, promotion, and optimization of health and abilities,
prevention of illness and injury, alleviation of suffering through the diagnosis and
treatment of human response, and advocacy in the care of individuals, families,
communities, and populations. (American Nurses Association, as cited in Moller
& McLoughlin, 2013)
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This definition also reflects the key tenets of SAMHSA’s framework for traumainformed care which include safety, trustworthiness and transparency, peer support,
collaboration and mutuality, empowerment, voice, cultural, gender issues (US
Department of Health and Human Services, 2014). Nurses have the ability to not only
fulfill this framework set forth by SAMHSA, but also have the ability to advocate that all
clinicians and personnel working within addiction treatment work from a traumainformed care perspective.
While there are numerous modalities to choose from, nurses have the ability to
work from a perspective of trauma-informed care. Working from a trauma-informed care
perspective means that a clinician understands how pervasive trauma exists in our
patients and communities, grasps the affect that trauma has on people, groups, various
societal systems, and takes this understanding and utilizes it to deliver care to the people
that are affected by trauma (US Department of Health and Human Services, 2014).
Viewing OUD as chronic disease, facilitates nurses’ ability to assist patients within a
trauma-informed care model. Furthermore, nurses are within a position to provide the
long-term, sustained care that these patients need.
One example of a model where nurses can be pivotal members of the treatment
team was developed in Massachusetts over the past 10-years in the Office-Based Opioid
Treatment -collaborative model (OBOT-B) utilizing buprenorphine (LaBelle, Han,
Bergeron, & Samet, 2016). This model is led with a nurse care manager assigned to each
patient that provides assessment, induction, education, drug/alcohol assessment, followup maintenance visits, and general counsel throughout their treatment program. This is
followed under the direction of a physician; however, the model recognizes that nurses
are better positioned to spend more time with the patient, have less of a case-load than the
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physician, and as mentioned earlier, have a philosophical grounding that allows them to
attend holistically to the patient. While this program is an exemplar, it still lacks a
focused assessment and further con-current treatment of OUD and trauma with a traumainformed care model.
No matter the model of choice, at the very least, it should include both nurses and
nurse practitioners working in tandem with other clinicians and team members that
function from a trauma-informed care perspective. This means that first and foremost as
nurses proceed into addiction medicine, they learn as much about the antecedents of
trauma and the sequelae from trauma as possible. These nurses should be relied on to
assess all patients universally for a history of trauma, and then make the determination
whether the patient needs a specific trauma informed approach.
If possible, keeping that same nurse/patient relationship would be essential for
developing a sense of belonging, trustworthiness, and safety. As the patient progresses, it
will be of great importance for the nurse to praise the patient when meeting all treatment
compliance indicators and be yet very empathetic and empowering when the patient may
have missed a compliance indicator or had another drug appear on a urine screen for
instance. By doing this the nurse will allow the patient to make mistakes, yet still feel
empowered to resume treatment.
Limitations to the Study
Data Mining
One limitation is related to the utilization of data mining procedures. Had the
electronic health record (EHR) been designed in a manner to easily gather data, this may
have given the study the ability to derive a more robust analysis of the data. For instance,
finding clinician input of PTSD and trauma symptoms resulted from pulling data from
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multiple locations in the EHR. If there was a formalized place to score patients as they
were assessed, there may have been an even greater number of patients identified with
PTSD or trauma histories as this is an often underdiagnosed group to begin with (Elhai et
al., 2012; Zimmerman & Mattia, 1999).
Motivation
An additional limitation is the inability to understand the motivation for treatment
success for CJS patients. Those CJS patients may have been involved in a drug treatment
court (DTG) or simply had an understanding that if found to having been using opioids,
they would be in violation of a probation or parole status. The motivation to avoid reincarceration is plausible but cannot be known as a result of this study. If this was their
motivation, this is concurrent with current literature that demonstrates that recidivism of
those in DTC’s has been shown to decrease for those with increased supervision, MAT,
and therapy (DeFulio et al., 2013; Jewell, Rose, Bush, & Bartz, 2017; Sevigny, Fuleihan,
& Ferdik, 2013; Shannon, Jones, Newell, & Neal, 2018). It should be noted that the
recidivism measured in these previous studies, with the exception of DeFulio et al.
(2013), is not based on opioid or drug use at follow-up, it is based on withdrawal from a
DTC program, reincarceration, or criminal offense. Following up for long-term periods,
even past probation or DTC enrollment, would help provide useful data to determine if
opioid use stays low after those initial motivations i.e. not returning to jail or prison, have
expired.
Pre-release Medication Treatment
A final CJS-related limitation is the inability to know if participants with CJS had
initiation to buprenorphine pre-release from incarceration. While the instances of
receiving buprenorphine pre-release from incarceration are limited, it is possible that
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some CJS patients may have received medication treatment pre-release. Gordon et al.
(2017) found that at 12-months post-release, those patients who had received
buprenorphine pre-release displayed increased buprenorphine use and longer time in
treatment. Due to this finding, it would be beneficial to know if some of those in the CJS
group received buprenorphine pre-release and therefore increased their treatment success
in this study.
As previous research has demonstrated that the longer the period of abstinence
from opioids (except buprenorphine or methadone), at least 5-years, the greater chance
patients have of long-term abstinence (Hser, Evans, Grella, Ling, & Anglin, 2015; Zhu et
al., 2018). Evaluating these patients for only a two year period may have limited the
ability to view long-term recovery.
Sample Characteristics
In regard to the sample, though a relatively large sample size was used, a limiting
factor was the homogenous makeup related to a mostly white, non-Hispanic, mostly from
Massachusetts sample. Additionally, it was not known from the sample data whether the
patients in the sample were managing an OUD from heroin or prescription opiates. Black
and Hispanic patients with an OUD are disproportionately suffering from an addiction to
heroin and not prescription opioids (Krawczyk, Feder, Fingerhood, & Saloner, 2017).
Earlier studies demonstrated that those in poverty, people of color, Hispanic ethnicity,
without a college education, and having an addiction to heroin were more likely to
receive methadone than buprenorphine (Hansen et al., 2013; Hatcher, Mendoza, &
Hansen, 2018). Recent studies have shown an increase in healthcare utilization for those
with an OUD both nationally after the implementation of the Affordable Care Act
(McKenna, 2017) and within Massachusetts after implementing a universal care model.
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However, despite these increases, black and Hispanic patients are still underserved in
terms of receiving buprenorphine treatment for OUD (Krawczyk et al., 2017).
Questions for Future Research
The findings suggest further study focused on whether the motivation for CJS
patients to be med adherent and less reliant on opioids is not being reincarcerated. This
may prove helpful to understand this motivation as we see an increase in the use of drug
courts and provide further evidence to those who would have us only treat those patients
with abstinence-based treatments and further incarceration. Further theoretical models
should be examined and adapted to direct evidence-based practice regarding CJS patients.
As mentioned earlier, knowing whether or not CJS patients have received
buprenorphine during incarceration would help provide further credence that this
population needs to be treated while incarcerated not only immediately before re-entry
but at the beginning of the incarceration experience.
Finally, it would be important to understand the impact of PTSD treatment on the
impact of MT treatment on patients with PTSD. Future research should examine both of
these constructs simultaneously. Understanding the individual and group counselor’s
theoretical approach may help elucidate if patients with PTSD have better MT outcomes
with or without specific PTSD treatment. It would also be beneficial to understand if
there is an impact of PTSD treatment type as this could help direct care for other patients
with similar circumstances.
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Conclusions and Implications
This study confirms that those with PTSD, trauma, or a CJS are at increased risk
for not only missing and withdrawing from treatment but are requiring far more attention
from treatment center staff to manage their recovery. The particular system of patient
management that this particular treatment center utilizes appears to have a successful
model that is improving the health of their patients, even those with PTSD, trauma, or
CJS. Those with PTSD/trauma/CJS are continuing to be medication adherent while at
the same time still using other drugs and missing treatment visits. This suggests that
these groups are struggling to continue their treatment despite accessing additional help
from staff. Additionally, women are a seeming to have the same issues in terms of
treatment compliance and need further study to direct care that is supportive to this
specific group of patients. The development of interventions specifically focused on
PTSD/trauma and CJS experiences would help mitigate this disruption in care.
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APPENDIX A
CLEAN SLATE LETTERS OF SUPPORT
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APPENDIX B
OPIOID DIAGNOSTIC CRITERIA
1. Opioids are often taken in larger amounts or over a longer period than was intended.
2. There is a persistent desire with unsuccessful effort to cut down or control opioid use.
3. A great deal of time is spent in activities necessary to obtain the opioid, use the opioid, or
recover from its effects.
4. Craving, or a strong desire or urge to use opioids.
5. Recurrent opioid use resulting in a failure to fulfill major role obligations at work, school, or
home.
6. Continued opioid use despite having persistent or recurrent social or interpersonal problems
caused or exacerbated by the effects of opioids.
7. Important social, occupational, or recreational activities are given up or reduced because of
opioid use.
8. Recurrent opioid use in situations in which it is physically hazardous.
9. Continued opioid use despite knowledge of having a persistent or recurrent physical or
psychological problem that is likely to have been caused or exacerbated by the substance.
10. Tolerance as defined by the following:
a.

A need for markedly increased amounts of opioids to achieve intoxication or
desired effect.

b. A markedly diminished effect with continued use of the same amount of an
opioid.
11. Withdrawal as manifested by the following:
a.

The characteristic opioid withdrawal syndrome.

b. Opioids (or a closely related substance) are taken to relieve or avoid withdrawal
syndrome.
(Diagnostic and statistical manual of mental disorders : DSM-5. (APA, 2013).
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